[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 181
1. Matsuhashi Y, Tasaka T, Uehara E, Kamei T, Tamura T, Nagai M: Successful therapy of pure red cell aplasia secondary to plasma cell dyscrasia with bolus methylprednisolone. Intern Med; 2001 Aug;40(8):802-4
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful therapy of pure red cell aplasia secondary to plasma cell dyscrasia with bolus methylprednisolone.
  • He was diagnosed with pure red cell aplasia (PRCA) associated with plasma cell dyscrasia.
  • Despite a markedly decreased red blood cell count (hematocrit 5.6%), the patient refused transfusion.
  • Reticulocytosis and recovery from anemia were observed on day 7 after the start of therapy.
  • Secondary PRCA following plasma cell dyscrasia is a rare disorder; the treatments for this rare condition are discussed.
  • [MeSH-major] Glucocorticoids / therapeutic use. Methylprednisolone / therapeutic use. Paraproteinemias / complications. Red-Cell Aplasia, Pure / drug therapy. Red-Cell Aplasia, Pure / etiology
  • [MeSH-minor] Aged. Humans. Injections, Intravenous. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11518129.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Glucocorticoids; X4W7ZR7023 / Methylprednisolone
  •  go-up   go-down


2. Mohri H: Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia. Am J Hematol; 2004 Dec;77(4):421-2
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resolution of acquired factor X deficiency with amyloidosis secondary to plasma cell dyscrasia.
  • [MeSH-minor] Aged. Drug Therapy, Combination. Female. Humans. Melphalan / administration & dosage. Melphalan / therapeutic use. Prednisone / administration & dosage. Prednisone / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Factor X Deficiency.
  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15551292.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


3. Sakakima M, Fujigaki Y, Tsuji T, Fukasawa H, Miyaji T, Naito K, Yamamoto T, Yonemura K, Ohnishi K, Hishida A: High dose chemotherapy and stem cell support in a patient of light- and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med; 2005 Sep;44(9):970-4
Genetic Alliance. consumer health - Light chain deposition disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High dose chemotherapy and stem cell support in a patient of light- and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein.
  • A 53-year-old man with nephrotic syndrome and severe renal failure was diagnosed with light- and heavy-chain deposition disease (LHCDD) by renal biopsy.
  • The patient had no monoclonal protein and mild marrow plasmacytosis (6%), but marrow plasma cells expressed CD19(-)CD56+ and predominant monoclonal kappa-chain, indicating plasma cell dyscrasia.
  • Conventional chemotherapy was ineffective and did not improve renal failure.
  • High dose chemotherapy/peripheral blood stem cell transplantation (HDC/PBSCT) was introduced even after hemodialysis to eliminate aberrant clone and normalization of bone marrow cell surface markers.
  • Immunophenotypic analysis of marrow cells facilitates clinical decision making regarding the use of HDC/PBSCT for LHCDD patients without monoclonal protein.
  • [MeSH-major] Heavy Chain Disease / therapy. Immunoglobulin Light Chains. Paraproteinemias / therapy
  • [MeSH-minor] Antigens, CD19 / metabolism. Antigens, CD56 / metabolism. Antineoplastic Agents / therapeutic use. Bone Marrow Cells / immunology. Combined Modality Therapy. Humans. Male. Middle Aged. Nephrotic Syndrome / drug therapy. Nephrotic Syndrome / therapy. Peripheral Blood Stem Cell Transplantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2005 Sep;44(9):915-6 [16258202.001]
  • (PMID = 16258214.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antigens, CD56; 0 / Antineoplastic Agents; 0 / Immunoglobulin Light Chains
  •  go-up   go-down


Advertisement
4. Altundag K, Kurt M, Islam R, Altundag O, Turen S: Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor. Med Hypotheses; 2006;66(2):444-5
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of plasma cell dyscrasia as a second primary malignancy may be low in postmenopausal breast cancer survivors treated with selective estrogen receptor modulator or aromatase inhibitor.
  • [MeSH-major] Aromatase Inhibitors / therapeutic use. Breast Neoplasms / drug therapy. Myelodysplastic Syndromes. Neoplasms, Second Primary. Postmenopause. Selective Estrogen Receptor Modulators / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15996830.001).
  • [ISSN] 0306-9877
  • [Journal-full-title] Medical hypotheses
  • [ISO-abbreviation] Med. Hypotheses
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Aromatase Inhibitors; 0 / Selective Estrogen Receptor Modulators
  •  go-up   go-down


5. Raj RS, Najeeb S, Aruna R, Pavithran K, Thomas M: Primary plasma cell leukemia occuring in the young. Indian J Cancer; 2003 Jul-Sep;40(3):116-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia occuring in the young.
  • Plasma Cell Leukemia (PCL) is a rare form of plasma cell dyscrasia.
  • Plasma cell leukemia has two variants: the primary form presents de novo in patients with no previous history of multiple myeloma (MM); the secondary form consists of a leukemic transformation in a previously recognized MM.
  • She was treated with combination chemotherapy (VAD).
  • Although she had a good response initially, later the disease progressed and she died 6 months after the diagnosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Leukemia, Plasma Cell / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adult. Disease Progression. Fatal Outcome. Female. Humans. Prognosis

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14716116.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


6. Sharabi Y, Raanani P, Shenkar A, Thaler M, Grossman E: Plasma cell dyscrasia with polyneuropathy--POEMS syndrome presenting with vasculitic skin lesions and responding to combination chemotherapy. Leuk Lymphoma; 2000 Dec;40(1-2):209-13
Genetic Alliance. consumer health - POEMS syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell dyscrasia with polyneuropathy--POEMS syndrome presenting with vasculitic skin lesions and responding to combination chemotherapy.
  • We report a 61-year-old male patient who presented with severe sensorimotor neuropathy, leg edema and skin lesions with M-paraprotein and 50% plasma cells in the bone marrow.
  • The patient was treated with aggressive combined chemotherapy, which induced improvement in both the clinical and laboratory parameters of his disease.
  • Our findings may shed light on the unknown pathogenesis of this syndrome and the successful results of treatment support the adoption of an aggressive therapeutic approach in symptomatic patients.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Diagnosis, Differential. Humans. Male. Middle Aged. Paraproteinemias / drug therapy. Paraproteinemias / etiology. Paraproteinemias / pathology. Polyneuropathies / drug therapy. Polyneuropathies / etiology. Polyneuropathies / pathology. Vasculitis / etiology. Vasculitis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426623.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


7. Jaccard A, Royer B, Bordessoule D, Brouet JC, Fermand JP: High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood; 2002 Apr 15;99(8):3057-9
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome.
  • We treated 5 patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome and multifocal bone lesions or diffuse bone marrow plasmacytic infiltration with high-dose therapy (HDT) and autologous blood stem cell transplantation.
  • In all cases, the treatment produced remission of plasma cell proliferation associated with marked improvement in the patients' performance status, neurologic symptoms, and other manifestations of the syndrome.
  • HDT with stem cell support should be investigated further as a therapeutic option in patients with POEMS syndrome and disseminated plasma cell dyscrasia.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Hematopoietic Stem Cell Transplantation. POEMS Syndrome / therapy
  • [MeSH-minor] Adult. Clone Cells / immunology. Clone Cells / pathology. Combined Modality Therapy. Dose-Response Relationship, Drug. Female. Humans. Immunoglobulins / blood. Immunoglobulins / urine. Male. Melphalan / administration & dosage. Middle Aged. Nervous System Diseases / etiology. Plasma Cells / immunology. Plasma Cells / pathology. Remission Induction. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11929800.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulins; Q41OR9510P / Melphalan
  •  go-up   go-down


8. Sanchorawala V, Seldin DC: An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid; 2007 Dec;14(4):261-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis.
  • AL amyloidosis is the most common form of systemic amyloidosis and is associated with an underlying plasma cell dyscrasia.
  • This review outlines an overview of high-dose intravenous melphalan and stem cell transplantation in the treatment of AL amyloidosis.
  • An algorithm of our recommendations for the treatment of AL amyloidosis is also outlined.
  • [MeSH-major] Amyloidosis / drug therapy. Amyloidosis / surgery. Melphalan / therapeutic use. Stem Cell Transplantation / methods
  • [MeSH-minor] Algorithms. Dose-Response Relationship, Drug. Humans. Myeloablative Agonists / administration & dosage. Myeloablative Agonists / therapeutic use. Practice Guidelines as Topic

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17968685.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloablative Agonists; Q41OR9510P / Melphalan
  • [Number-of-references] 47
  •  go-up   go-down


9. Horta P, Quevedo I: [Poems syndrome. Report of one case]. Rev Med Chil; 2004 Apr;132(4):485-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Síndrome de Poems: caso clínico.
  • Poems syndrome (polyneuropathy, organomegaly, endocrine abnormality, M-protein, plasma cell dyscrasia, and skin lesions) is a plasma cell dyscrasia whose pathogenesis is unknown.
  • The subsequent work up revealed an IgA type monoclonal gammopathy, hepatomegaly, hyperestrogenism, primary adrenal failure, hypothyroidism, hyperpigmentation and erythematous lesions in the skin and ankle edema.
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Female. Humans. Immunoglobulin A / analysis. Middle Aged. Paraproteinemias / diagnosis. Paraproteinemias / drug therapy. Prednisone / therapeutic use

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15382521.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Immunoglobulin A; VB0R961HZT / Prednisone
  •  go-up   go-down


10. Silapunt S, Chon SY: Generalized necrobiotic xanthogranuloma successfully treated with lenalidomide. J Drugs Dermatol; 2010 Mar;9(3):273-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Necrobiotic xanthogranuloma (NXG) presents a therapeutic challenge to clinicians.
  • Generalized NXG has limited treatment options.
  • A patient presented to the authors with generalized NXG associated with monoclonal gammopathy of unknown significance (MGUS), a plasma cell dyscrasia considered to be a precursor to multiple myeloma.
  • The patient was treated with lenalidomide, a derivative of thalidomide with efficacy in treatment of multiple myeloma.
  • [MeSH-major] Granuloma / drug therapy. Necrobiotic Disorders / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Aged. Aged, 80 and over. Dexamethasone / therapeutic use. Humans. Male. Monoclonal Gammopathy of Undetermined Significance / drug therapy

  • Genetic Alliance. consumer health - Xanthogranuloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232591.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


11. Jacob SE, Fien S, Kerdel FA: Scleromyxedema, a positive effect with thalidomide. Dermatology; 2006;213(2):150-2
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Scleromyxedema is a rare dermatological disorder marked by widespread symmetric 2- to 3-mm, firm, waxy, closely spaced papules involving the hands, forearms, face, neck, upper trunk and thighs.
  • The most common extracutaneous manifestation of scleromyxedema is a benign plasma cell dyscrasia.
  • Treatment of scleromyxedema is limited by the lack of long-term results, toxicity and significant adverse side effects.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Scleromyxedema / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Middle Aged. Paraproteins / drug effects. Paraproteins / metabolism. Severity of Illness Index

  • Genetic Alliance. consumer health - Scleromyxedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 16902294.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Paraproteins; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


12. Liu YC, Miyazawa K, Sashida G, Kodama A, Ohyashiki K: Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly. Cancer Genet Cytogenet; 2006 Aug;169(1):69-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deletion (20q) as the sole abnormality in Waldenström macroglobulinemia suggests distinct pathogenesis of 20q11 anomaly.
  • The deletion of the long arm of chromosome 20, or del(20q), is a common cytogenetic abnormality in various myeloid disorders but is less commonly seen in lymphoid neoplasms.
  • Reviewing all 11 reported cases of plasma cell dyscrasia possessing sole del(20q), including our case, none of 4 cases with del(20q) as an initial anomaly developed myelodysplastic syndrome-acute myeloid leukemia (MDS/AML), but at least 3 cases with del(20q) appearing after chemotherapy developed MDS/AML at or after the time of del(20q).
  • We propose that the del(20q) may have different clinical significance in plasma cell dyscrasia: one is when del(20q) appears at diagnosis and may involve the initial event of oncogenesis, and the other is when del(20q) appears after treatment and is associated with therapy-related and potential MDS/AML risk.

  • Genetic Alliance. consumer health - Waldenstrom macroglobulinemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875940.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA: Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol; 2010 Jul;150(1):28-38
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On February 25, 2009, a panel of international experts on plasma cell dyscrasia and skeletal disease met to discuss monoclonal gammopathy of undetermined significance (MGUS).
  • This non-malignant B-cell disorder is the most common plasma cell dyscrasia and is associated with an increased risk of developing serious B-cell disorders.
  • The panel also addressed the identification and treatment of MGUS-related skeletal problems, thromboembolic events and neurological complications.
  • The following consensus statement outlines the conclusions and marks the first time that a consensus statement for the screening and treatment of MGUS has been clearly stated.
  • [MeSH-minor] Aged. Bone Diseases, Metabolic / diagnosis. Bone Diseases, Metabolic / etiology. Cell Transformation, Neoplastic. Disease Progression. Humans. Long-Term Care / methods. Long-Term Care / standards. Mass Screening / methods. Mass Screening / organization & administration. Middle Aged. Peripheral Nervous System Diseases / drug therapy. Peripheral Nervous System Diseases / etiology. Prognosis. Risk Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20507313.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] England
  • [Number-of-references] 86
  •  go-up   go-down


14. Bose P, Thompson CL, Gandhi DG, Ghabach BS, Ozer H: Response of AIDS-related plasmablastic lymphoma (PBL) to bortezomib. J Clin Oncol; 2009 May 20;27(15_suppl):e19562

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e19562 PBL are a group of highly aggressive neoplasms originally described in the oral cavity and jaws of HIV-infected patients.
  • They are terminally differentiated B-cell neoplasms, and typically lack common B-cell markers but uniformly express plasma cell markers.
  • Flow cytometry was negative for CD45 and all common epithelial, T-cell and B-cell markers, but was positive for CD138 and p63(VS38c).
  • Highly active anti-retroviral therapy was begun.
  • Anthracycline-based chemotherapy was avoided due to persistent hyperbilirubinemia.
  • PET/CT on day 7 showed a marked decrease in hypermetabolism after only 2 doses, signifying a dramatic treatment response.
  • The prognosis of PBL is poor, with a median survival of about 6 months in most series.
  • The WHO classifies PBL as a variant of diffuse large B-cell lymphoma.
  • However, studies of their immunophenotype and molecular histogenesis suggest that PBL are more closely related to plasma cell neoplasms.
  • Bortezomib is a proteasome inhibitor widely used in multiple myeloma and mantle cell lymphoma.
  • We chose bortezomib based on our patient's poor performance status and immune function, the desire to avoid combination chemotherapy, and translocations involving the immunoglobulin heavy chain gene locus (8;14) similar to those seen in multiple myeloma(4;14, 14;16) and mantle cell lymphoma(11;14).
  • A shift in the paradigm of treatment of PBL towards agents effective in plasma cell malignancies may be necessary.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Sjak-Shie NN, Vescio RA, Berenson JR: Recent advances in multiple myeloma. Curr Opin Hematol; 2000 Jul;7(4):241-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our understanding of the pathophysiology underlying myeloma continues to expand, but the cause of this plasma cell dyscrasia remains unclear.
  • The roles of cytogenetic abnormalities as well as aberrant angiogenesis and cytokine expression in the etiology of myeloma continue to be explored and may lead to future therapeutic strategies.
  • Transplantation in myeloma is rarely curative but offers clinical benefit not only for young but possibly for older myeloma patients as well.
  • Finally, thalidomide offers significant clinical benefit to patients with myeloma previously refractory to multiple agents, and its role in early stages of the disease is under investigation.
  • [MeSH-major] Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Bone Marrow / virology. Bone Marrow Transplantation. Chromosome Aberrations. Combined Modality Therapy. Cytokines / physiology. Diphosphonates / therapeutic use. Growth Substances / physiology. Hematopoietic Stem Cell Transplantation. Herpesviridae Infections / complications. Herpesviridae Infections / diagnosis. Herpesvirus 8, Human / isolation & purification. Herpesvirus 8, Human / pathogenicity. Humans. Neoplasm Proteins / physiology. Neovascularization, Pathologic. Osteolysis / drug therapy. Osteolysis / etiology. Osteolysis / radiotherapy. Plasma Cells / pathology. Remission Induction. Salvage Therapy. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10882180.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Cytokines; 0 / Diphosphonates; 0 / Growth Substances; 0 / Neoplasm Proteins; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 75
  •  go-up   go-down


16. Ardashev VN, Potekhin NP, Rukavitsyn OA, Borisov AG, Malysheva SA: [A case of primary amyloidosis]. Klin Med (Mosk); 2006;84(6):56-9
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Diagnostics of primary (AL) amyloidosis is difficult enough; treatment of this disease in not less difficult or more adequate.
  • Because of similarity of the pathogenesis of AL-amyloidosis and that of multiple myeloma, similar therapeutic regimens, directed towards depression of plasma cell dyscrasia, are used in both cases: administration of melphalan in various doses together with prednisolone, administration of vincristine, adriablastine and dexamethasone, as well as high-dose chemotherapy with melphalan and autologic stem cell transplantation.
  • This therapeutic approach makes it possible to reach clinico-laboratory remission and prolong the life of patients with AL-amyloidosis.
  • The article contains a case description of a patient with AL-amyloidosis, who underwent a successful high-dose melphalan therapy with subsequent autologic stem cell transplantation.
  • [MeSH-major] Amyloidosis / diagnosis. Amyloidosis / pathology. Antineoplastic Agents, Alkylating / therapeutic use. Melphalan / therapeutic use
  • [MeSH-minor] Diagnosis, Differential. Drug Therapy, Combination. Humans. Immunoglobulin G / immunology. Male. Middle Aged. Prednisolone / therapeutic use

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875072.001).
  • [ISSN] 0023-2149
  • [Journal-full-title] Klinicheskaia meditsina
  • [ISO-abbreviation] Klin Med (Mosk)
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin G; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


17. De Jager E, Bieger R, Castel A, Kluin PM: Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy. Eur J Haematol; 2001 May;66(5):352-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an acquired haemorrhagic diathesis due to factor X deficiency with chemotherapy.
  • A 70-yr-old woman presented with a severe haemorrhagic diathesis due to an acquired factor X deficiency.
  • A plasma infusion study showed that exogenous factor X was eliminated very effectively from the patient's circulation.
  • A bone marrow biopsy was consistent with plasma cell dyscrasia.
  • Treatment with intermittent chemotherapy, consisting of vincristine, cytoxan and prednisone, yielded definite clinical and laboratory improvement.
  • [MeSH-major] Factor X Deficiency / complications. Hemorrhagic Disorders / drug therapy. Hemorrhagic Disorders / etiology
  • [MeSH-minor] Aged. Amyloidosis / complications. Antineoplastic Agents / therapeutic use. Bence Jones Protein / urine. Biopsy. Bone Marrow / pathology. Cyclophosphamide / therapeutic use. Female. Humans. Paraproteinemias / pathology. Partial Thromboplastin Time. Prednisone / therapeutic use. Prothrombin Time. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Factor X Deficiency.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11422417.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; 9006-99-9 / Bence Jones Protein; VB0R961HZT / Prednisone
  •  go-up   go-down


18. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR: Amyloidosis. Best Pract Res Clin Haematol; 2005;18(4):709-27
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amyloidosis is an uncommon plasma-cell dyscrasia with an incidence of eight patients per million per year.
  • Newly developed therapeutic strategies, involving high-dose and intermediate-dose chemotherapy, have evolved in the last 3 years.
  • This paper reviews a diagnostic pathway clinicians can use to diagnose the disorder, assess a patient's prognosis, and logically plan a therapeutic strategy.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Humans. Plasma Cells / pathology. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16026746.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 79
  •  go-up   go-down


19. Zeier M, Perz J, Linke RP, Donini U, Waldherr R, Andrassy K, Ho AD, Goldschmidt H: No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement. Nephrol Dial Transplant; 2003 Dec;18(12):2644-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
  • BACKGROUND: High-dose chemotherapy followed by autologous blood stem cell transplantation induces remission of plasma cell dyscrasia in patients with AL amyloidosis.
  • The impact of this treatment on the glomerular amyloid mass is still unknown.
  • METHODS: In the present study, the quantity of the renal amyloid mass before and more than 3 years after high-dose melphalan treatment and autologous blood stem cell transplantation was assessed in two patients.
  • At the time of the second renal biopsy, both patients were in complete remission without detectable serum and urinary monoclonal IgA-lambda and a normal percentage of plasma cells in the bone marrow.
  • RESULTS: In both patients with biopsy-proven AL amyloidosis, urinary protein excretion decreased from 7 g/24 h to <2 g/24 h more than 3 years after autologous blood stem cell transplantation.
  • CONCLUSION: Despite complete remission of the plasma cell dyscrasia and improvement of glomerular permeability, the amount of glomerular amyloid mass did not regress.
  • [MeSH-major] Amyloid / analysis. Amyloidosis / physiopathology. Antineoplastic Agents, Alkylating / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Kidney Diseases / physiopathology. Melphalan / therapeutic use. Paraproteinemias / physiopathology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14605290.001).
  • [ISSN] 0931-0509
  • [Journal-full-title] Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • [ISO-abbreviation] Nephrol. Dial. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


20. Zelichowski G, Lubas A, Wańkowicz Z: [Advances in diagnosis and treatment of AL amyloidosis]. Pol Merkur Lekarski; 2008 Apr;24(142):340-5
MedlinePlus Health Information. consumer health - Kidney Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in diagnosis and treatment of AL amyloidosis].
  • AL amyloidosis is a systemic disease characterized by extracellular amyloid deposition in tissues, causing progressive dysfunction of affected organs.
  • The aim of therapy is the reduction of monoclonal light chains, by suppressing the underlying plasma cell dyscrasia.
  • Recent therapeutic strategies involve intermediate-dose chemotherapy or high-dose melphalan supported by peripheral blood stem cell transplantation.
  • Alternative therapeutic approaches include thalidomide, lenalidomide, iododoxorubicin, etanercept and rituximab.
  • This paper reviews the pathogenesis, diagnosis and therapy of the AL amyloidosis, focusing on clinico-morphological symptoms of renal involvement, monitoring of treatment response and supportive therapy.
  • [MeSH-major] Amyloidosis / diagnosis. Amyloidosis / therapy. Kidney Diseases / diagnosis. Kidney Diseases / therapy
  • [MeSH-minor] Amyloid / metabolism. Antineoplastic Agents / therapeutic use. Humans. Immunotherapy. Nephrotic Syndrome / etiology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18634370.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antineoplastic Agents
  • [Number-of-references] 48
  •  go-up   go-down


21. Paciocco G, Bossone E, Erba H, Rubenfire M: Reversible pulmonary hypertension in POEMS syndrome--another etiology of triggered pulmonary vasculopathy? Can J Cardiol; 2000 Aug;16(8):1007-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes (POEMS) syndrome, a plasma cell dyscrasia associated with pulmonary hypertension, has been treated in the past with anticytokine strategies with a poor outcome.
  • [MeSH-minor] Adrenal Cortex Hormones / administration & dosage. Diuretics / administration & dosage. Drug Therapy, Combination. Female. Humans. Middle Aged. Nifedipine / administration & dosage. Raynaud Disease / complications. Raynaud Disease / diagnosis. Raynaud Disease / drug therapy. Remission Induction. Time Factors

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Pulmonary Hypertension.
  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • Hazardous Substances Data Bank. Nifedipine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10978936.001).
  • [ISSN] 0828-282X
  • [Journal-full-title] The Canadian journal of cardiology
  • [ISO-abbreviation] Can J Cardiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] CANADA
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Diuretics; I9ZF7L6G2L / Nifedipine
  • [Number-of-references] 17
  •  go-up   go-down


22. Miwa A: [Advances in therapeutic strategies for multiple myeloma]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2200-16
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Advances in therapeutic strategies for multiple myeloma].
  • Multiple myeloma (MM) remains an incurable plasma cell dyscrasia characterized by bone marrow failure, bone disease, renal disease and other complications.
  • The clinical pictures show extensive diversity which is based on complex cytogenetic abnormalities, and lot of interactions between myeloma cell and bone marrow stroma.
  • Recently, advances in understanding the biology of myeloma including the function of proteasome, molecular chaperons on the folding of intracellular proteins as well as signal transduction pathway, apoptosis-inducing cascade and oncogenomics, have brought about the development of several new therapeutic strategies.
  • [MeSH-major] Multiple Myeloma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Cells / drug effects. Boronic Acids / therapeutic use. Bortezomib. Cell Communication / drug effects. Humans. Proteasome Inhibitors. Pyrazines / therapeutic use. Signal Transduction / drug effects. Thalidomide / analogs & derivatives. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079620.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Proteasome Inhibitors; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; F0P408N6V4 / lenalidomide
  • [Number-of-references] 28
  •  go-up   go-down


23. Foguem C, Kantelip B, Deconinck E, Hafsaoui C, Méaux-Ruault N, Gil H, Magy-Bertrand N, Dupond JL: [Kappa light chain deposition disease, presenting as Sjögren's syndrome, successfully treated by high-dose melphalan and autologous blood stem transplantation]. Rev Med Interne; 2009 Jan;30(1):49-52
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Kappa light chain deposition disease, presenting as Sjögren's syndrome, successfully treated by high-dose melphalan and autologous blood stem transplantation].
  • [Transliterated title] Maladie de Randall, simulant une maladie de Gougerot-Sjögren, traitée avec succès par chimiothérapie et autogreffe de moelle osseuse.
  • INTRODUCTION: Light chain deposition disease is a systemic disorder characterised by tissue deposition of monoclonal immunoglobulin light chains without tinctorial properties.
  • CASE REPORT: We report a case of light chain deposition disease associated with plasma cell dyscrasia presenting as sicca syndrome with salivary glands hypertrophy and polyneuropathy successfully treated by high dose melphalan and autologous blood stem transplantation.
  • CONCLUSION: Light chain deposition disease should be recognized as an aetiology of sicca syndrome and peripheral neuropathy.
  • Further studies should assess the prevalence of sicca syndrome in light chain deposition disease and better characterise the neurological manifestations.


24. Thakkar SG, Isada C, Smith J, Karam MA, Reed J, Tomford JW, Englund K, Richmond M, Licata A, Hatch C, Hussein MA: Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias. Med Oncol; 2006;23(1):51-6
MedlinePlus Health Information. consumer health - Osteonecrosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Jaw complications associated with bisphosphonate use in patients with plasma cell dyscrasias.
  • We report 17 cases of patients with plasma cell dyscrasia being treated with bisphosphonate who developed osteonecrosis/osteomyelitis of the jaw.
  • Six of the 17 did receive both agents at some time and all of these individuals were receiving zoledronic acid at diagnosis.
  • Patients should have a full dental examination at the time of diagnosis of the plasma cell dyscrasia especially if bisphosphonates are to be considered as part of the therapy.
  • Following the dental procedure we would re-introduce bisphosphonates only after the healing process is complete.
  • [MeSH-major] Diphosphonates / adverse effects. Jaw Diseases / chemically induced. Osteonecrosis / chemically induced. Paraproteinemias / drug therapy

  • MedlinePlus Health Information. consumer health - Jaw Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2002 Sep 1;20(17):3719-36 [12202673.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1080-4 [12006522.001]
  • [Cites] Br J Haematol. 2004 Nov;127(3):299-304 [15491289.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Physiol Res. 1998;47(4):237-40 [9803469.001]
  • [Cites] Rheumatology (Oxford). 2002 Mar;41(3):346-7 [11934975.001]
  • [Cites] J Orthop Res. 2005 Jul;23(4):862-8 [16023001.001]
  • [Cites] J Periodontol. 2002 Jul;73(7):813-22 [12146541.001]
  • [Cites] Endocr Rev. 1998 Feb;19(1):80-100 [9494781.001]
  • [Cites] Calcif Tissue Int. 1987 Dec;41(6):326-31 [3124942.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] J Pharmacol Exp Ther. 2002 Sep;302(3):1055-61 [12183663.001]
  • [Cites] J Oral Maxillofac Surg. 2004 May;62(5):527-34 [15122554.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] Cancer J. 2001 Sep-Oct;7(5):377-87 [11693896.001]
  • [Cites] J Bone Miner Res. 2003 Nov;18(11):2016-22 [14606515.001]
  • [Cites] Cancer. 2001 Apr 1;91(7):1191-200 [11283917.001]
  • [Cites] Cranio. 2003 Apr;21(2):110-5 [12723856.001]
  • [Cites] J Oral Maxillofac Surg. 2003 Sep;61(9):1115-7 [12966493.001]
  • (PMID = 16645229.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid; OYY3447OMC / pamidronate
  •  go-up   go-down


25. Kapur U, Barton K, Fresco R, Leehey DJ, Picken MM: Expanding the pathologic spectrum of immunoglobulin light chain proximal tubulopathy. Arch Pathol Lab Med; 2007 Sep;131(9):1368-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: In plasma cell dyscrasias, involvement of the distal tubules is frequent and well characterized.
  • In contrast, proximal tubules have only rarely been reported to show diagnostic pathology such as intracytoplasmic crystals.
  • OBJECTIVE: To look for additional morphologic features that might be helpful in the diagnosis of proximal tubulopathy associated with an underlying plasma cell dyscrasia.
  • By light microscopy, only 1 patient had focal rhomboid crystals in the proximal tubular epithelium; all other biopsies failed to show any discernible pathology within the proximal tubules or elsewhere in the kidney.
  • By electron microscopy, proximal tubules from 2 patients showed crystals with a latticelike structure, whereas the remaining 3 patients had only prominent phagolysosomes.
  • Post-kidney biopsy, all patients were diagnosed with multiple myeloma or plasma cell dyscrasia.
  • One patient developed renal failure and had recurrence of crystals in the allograft.
  • CONCLUSIONS: Light chain proximal tubulopathy may be associated with the presence of crystals or with the presence of phagolysosomes with light chain restriction as the sole abnormality.
  • [MeSH-major] Fanconi Syndrome / metabolism. Fanconi Syndrome / pathology. Immunoglobulin Light Chains / metabolism. Kidney Tubules, Proximal / metabolism. Kidney Tubules, Proximal / pathology. Paraproteinemias / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Pathol Lab Med. 2008 Jan;132(1):13. Leehy, David J [corrected to Leehey, David J]
  • (PMID = 17824791.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  •  go-up   go-down


26. Lizis-Kolus K, Kowalska A, Nowakowska-Domagała M: [The POEMS syndrome with coexisting endocrinopathy--case report]. Endokrynol Pol; 2007 May-Jun;58(3):238-43
Genetic Alliance. consumer health - POEMS syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of a woman with unique multisystem disorder--POEMS syndrome and endocrine abnormalities coexisting with it.
  • Association between plasma cell dyscrasia and polyneuropathy, was described in 1956 year by Crow.
  • Within 3 years of the first symptoms, she developed hypogonadism hypergonadotropic.
  • Due to the progression of the disease, a thalidomide was used in therapy (it is anti-VEGF agent).
  • One of the side effects of the treatment of thalidomide is the progression of polyneuropathy, which was observed in this patient.
  • After finishing this therapy she received chemotherapy.
  • This case report imposes the necessity of constants observation of patients with POEMS syndrome because there is a possibility of their developing other disorders.
  • In the event of coexistence polyneuropathy and plasma cell dyscrasia, this disease should be taken into consideration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940990.001).
  • [ISSN] 0423-104X
  • [Journal-full-title] Endokrynologia Polska
  • [ISO-abbreviation] Endokrynol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


27. Comenzo RL: Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw; 2007 Feb;5(2):179-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amyloidosis is a rare disease in which a specific protein is deposited as aggregated interstitial fibrils that can compromise organ function and lead to death.
  • Immunoglobulin (Ig) light-chain amyloidosis (AL), caused by the monoclonal gammopathy of a plasma cell dyscrasia, is the most common type.
  • A hereditary type is also caused by mutant transthyretin and other proteins.
  • In AL, circulating monoclonal Ig light chains can be measured with the free light-chain (FLC) assay and provide a target for therapy to eliminate the underlying plasma cell dyscrasia while supporting the patient's organ function.
  • For patients with limited organ involvement, intravenous melphalan in doses from 100 to 200 mg/m2 with autologous stem cell support (SCT) is an effective approach and, when followed at 3 months post-SCT with adjuvant thalidomide and dexamethasone for persistent plasma cell disease, has a 1-year hematologic response rate of 77%.
  • Monthly oral melphalan and dexamethasone for 1 year can also be effective therapy for patients too sick for SCT (67% response rate).
  • For patients with advanced cardiac involvement, the prognosis remains guarded even with treatment.
  • Drugs effective in multiple myeloma are usually active in AL, depending on side effects.
  • [MeSH-major] Amyloidosis / drug therapy. Melphalan / therapeutic use. Myeloablative Agonists / therapeutic use. Paraproteinemias / drug therapy. Stem Cell Transplantation
  • [MeSH-minor] Combined Modality Therapy. Glucocorticoids / therapeutic use. Humans. Immunoglobulin Light Chains / physiology. Immunosuppressive Agents / therapeutic use. Organ Transplantation

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335687.001).
  • [ISSN] 1540-1405
  • [Journal-full-title] Journal of the National Comprehensive Cancer Network : JNCCN
  • [ISO-abbreviation] J Natl Compr Canc Netw
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunoglobulin Light Chains; 0 / Immunosuppressive Agents; 0 / Myeloablative Agonists; Q41OR9510P / Melphalan
  • [Number-of-references] 51
  •  go-up   go-down


28. Mak YK, Chan CH, Chen YT, Lau SM, So CC, Wong KF: Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia. Clin Lab Haematol; 2003 Feb;25(1):55-8
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consolidation therapy with autologous blood stem cell transplantation in a patient with primary plasma cell leukaemia.
  • Primary plasma cell leukaemia (PPCL) is a rare form of plasma cell dyscrasia.
  • Conventional melphalan-based treatment is often ineffective, with a reported median survival of 2-7 months only.
  • We report a 53-year-old man with PPCL who was treated with four cycles of combination chemotherapy including vincristine, adriamycin and dexamethasone that resulted in a good partial remission.
  • High-dose melphalan 200 mg/m2 and autologous peripheral blood stem cell (PBSC) rescue was then given 6 months after diagnosis.
  • Maintenance interferon-alpha was started 8 weeks after transplantation with good drug compliance.
  • In conclusion, high-dose therapy followed by autologous stem cell rescue is a feasible option for PPCL that can result in a reasonably sustained remission.
  • [MeSH-major] Leukemia, Plasma Cell / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Interferon-alpha / therapeutic use. Male. Middle Aged. Remission Induction / methods. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12542443.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


29. Danilatou V, Liapi D, Psyllaki M, Chatzivasili A, Chronaki I, Heliakis P: Neurofibromatosis type I and smoldering multiple myeloma: a case report. Hematology; 2006 Feb;11(1):45-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type I and smoldering multiple myeloma: a case report.
  • During follow-up period she remained stable in an excellent clinical condition without requiring any therapy for almost 4 years.
  • Subsequent evaluations of the disease showed a dramatic reduction of IgA paraprotein to below half the initial value.
  • We will discuss the probable pathogenesis of plasma cell dyscrasia in NF1 patients, as well as the likely antimyeloma activity of biphoshonates.
  • [MeSH-major] Bone Density Conservation Agents / administration & dosage. Diphosphonates / administration & dosage. Multiple Myeloma / drug therapy. Multiple Myeloma / etiology. Neurofibromatosis 1 / complications. Neurofibromatosis 1 / drug therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Neurofibromatosis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16522549.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Immunoglobulin A; 0 / Paraproteins
  •  go-up   go-down


30. Schonland SO, Perz JB, Hundemer M, Hegenbart U, Kristen AV, Hund E, Dengler TJ, Beimler J, Zeier M, Singer R, Linke RP, Ho AD, Goldschmidt H: Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation; 2005 Sep 27;80(1 Suppl):S160-3
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.
  • Systemic amyloid light chain amyloidosis is a protein conformation disorder caused by a clonal plasma cell dyscrasia.
  • Symptoms result from fibrillar extracellular deposits in kidney, heart, liver, gut, peripheral nervous system and other tissues.
  • Using conventional chemotherapy, the median survival could be prolonged by 4 months.
  • Treatment with high-dose melphalm (HDM) and autologous stem cell transplantation (ASCT) of selected patients has been shown to arrest and even to reverse the disease course.
  • This procedure however remains controversial because treatment related mortality (TRM) in AL amyloidosis is substantially higher (15-40%) than in multiple myeloma (<5%).
  • Here we review recent results of ASCT, eligibility criteria for HDM and report our own treatment results in 41 patients.
  • [MeSH-major] Amyloidosis / therapy. Immunoglobulin Light Chains. Melphalan / therapeutic use. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Transplantation, Autologous

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16286897.001).
  • [ISSN] 0041-1337
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  •  go-up   go-down


31. Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M: Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica; 2010 Feb;95(2):311-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.
  • In multiple myeloma, peripheral neuropathy has for a long time been considered as mainly secondary to the plasma cell dyscrasia itself.
  • With the advent of new targeted drugs such as thalidomide and bortezomib, the iatrogenic neurotoxicity has become the leading cause of peripheral neuropathy.
  • This review discusses the pathogenesis, incidence, risk factors, diagnosis, characteristics, and management of peripheral neuropathy related to new multiple myeloma drugs, mainly bortezomib and thalidomide.
  • The mechanisms involved depend on the agents used, patient's medical history, and duration of exposure and/or treatment doses or sequence.
  • Diagnosis of such peripheral neuropathy is often easier than treatment.
  • Finally, early detection of peripheral neuropathy and the use of dose adjustment algorithms as in the case of bortezomib, should help reduce the side effects while maintaining anti-tumor efficacy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Boronic Acids / adverse effects. Multiple Myeloma / drug therapy. Peripheral Nervous System Diseases / chemically induced. Pyrazines / adverse effects. Thalidomide / adverse effects

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2005 Jun;129(6):776-83 [15953004.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Best Pract Res Clin Haematol. 2005;18(4):673-88 [16026744.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):3-4 [16397016.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):273-80 [16397052.001]
  • [Cites] Oncologist. 2006 Jan;11(1):51-61 [16401713.001]
  • [Cites] Br J Haematol. 2006 Mar;132(5):584-93 [16445831.001]
  • [Cites] N Engl J Med. 2006 Mar 9;354(10):1021-30 [16525139.001]
  • [Cites] Neurology. 2006 Mar 28;66(6):917-8 [16567713.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Haematologica. 2006 Jul;91(7):1001 [16757419.001]
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4507-14 [16940275.001]
  • [Cites] Blood. 2006 Oct 1;108(7):2165-72 [16772605.001]
  • [Cites] Haematologica. 2006 Nov;91(11):1498-505 [17043025.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3458-64 [16840727.001]
  • [Cites] Leuk Lymphoma. 2006 Nov;47(11):2276-9 [17107897.001]
  • [Cites] Exp Neurol. 2007 Mar;204(1):317-25 [17214983.001]
  • [Cites] J Pain. 2007 Apr;8(4):296-306 [17175202.001]
  • [Cites] Neurology. 2007 Aug 7;69(6):573-81 [17679676.001]
  • [Cites] Cancer. 2007 Sep 1;110(5):1042-9 [17654660.001]
  • [Cites] J Clin Oncol. 2007 Oct 1;25(28):4452-8 [17785704.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3281-90 [17591945.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2123-32 [18032762.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):46-55 [17325847.001]
  • [Cites] N Engl J Med. 2007 Nov 22;357(21):2133-42 [18032763.001]
  • [Cites] Blood. 2008 Apr 15;111(8):3968-77 [18245666.001]
  • [Cites] Cell Cycle. 2008 Apr 1;7(7):940-9 [18414063.001]
  • [Cites] Hematol Oncol. 2008 Jun;26(2):55-65 [18324611.001]
  • [Cites] Clin Lymphoma Myeloma. 2008 Jun;8(3):146-52 [18650177.001]
  • [Cites] Blood. 2008 Sep 1;112(5):1593-9 [18574024.001]
  • [Cites] N Engl J Med. 2008 Aug 28;359(9):906-17 [18753647.001]
  • [Cites] J Clin Oncol. 2008 Sep 20;26(27):4519-20 [18802169.001]
  • [Cites] Clin Neurophysiol. 2008 Nov;119(11):2507-12 [18829381.001]
  • [Cites] J Peripher Nerv Syst. 2008 Dec;13(4):267-74 [19192066.001]
  • [Cites] J Peripher Nerv Syst. 2008 Dec;13(4):275-82 [19192067.001]
  • [Cites] Br J Haematol. 2009 Mar;144(6):895-903 [19170677.001]
  • [Cites] Expert Opin Investig Drugs. 2009 Jun;18(6):861-8 [19466875.001]
  • [Cites] Blood. 2009 Jul 23;114(4):772-8 [19471019.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Muscle Nerve. 2001 Aug;24(8):1050-7 [11439380.001]
  • [Cites] Leukemia. 2001 Aug;15(8):1274-6 [11480571.001]
  • [Cites] Food Chem Toxicol. 2002 Oct;40(10):1449-51 [12387307.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4319-23 [12409330.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4420-7 [12431963.001]
  • [Cites] Neurology. 2002 Dec 24;59(12):1872-5 [12499476.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 17):34-8 [12520483.001]
  • [Cites] Neurology. 2003 Mar 11;60(5):877-8 [12629253.001]
  • [Cites] Diabetes Care. 2003 Apr;26(4):1322-3 [12663627.001]
  • [Cites] N Engl J Med. 2003 Jun 26;348(26):2609-17 [12826635.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1147-9 [12916866.001]
  • [Cites] N Engl J Med. 2003 Sep 25;349(13):1287-8; author reply 1287-8 [14510013.001]
  • [Cites] Neurology. 2003 Nov 11;61(9):1297-300 [14610145.001]
  • [Cites] Leuk Lymphoma. 2003 Nov;44(11):1943-6 [14738147.001]
  • [Cites] Eur J Haematol. 2004 Jun;72(6):403-9 [15128418.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3839-52 [15173093.001]
  • [Cites] Neurology. 2004 Jun 22;62(12):2291-3 [15210898.001]
  • [Cites] Cancer. 2004 Aug 15;101(4):790-5 [15305411.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1968 Dec;31(6):543-51 [4303800.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] J Neurol. 1986 Apr;233(2):83-9 [3009724.001]
  • [Cites] Cancer Invest. 1990;8(2):147-59 [2400936.001]
  • [Cites] Ann Oncol. 1998 Jul;9(7):739-44 [9739440.001]
  • [Cites] Pain. 1999 Oct;83(1):85-90 [10506675.001]
  • [Cites] J Appl Toxicol. 2004 Nov-Dec;24(6):497-500 [15558839.001]
  • [Cites] Clin Lymphoma. 2004 Dec;5(3):163-71 [15636691.001]
  • [Cites] Eur J Haematol. 2005 Mar;74(3):212-6 [15693790.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3828-36 [15867381.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):755-62 [15953001.001]
  • (PMID = 20139393.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC2817035
  •  go-up   go-down


32. Harnalikar M, Pande S, Kharkar V, Khopkar U: Keratotic vascular papules over the feet: a case of Waldenström's macroglobulinaemia-associated cutaneous macroglobulinosis. Clin Exp Dermatol; 2010 Apr;35(3):278-81
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Waldenström's macroglobulinaemia (WM) is a plasma-cell dyscrasia characterized by the monoclonal proliferation of lymphoplasmacytes.
  • A 48-year-old man presented with a 4-year history of multiple painful, hyperkeratotic deep-seated papules over the pressure areas of both soles.
  • The patient received five cycles of chemotherapy, resulting in nearly complete resolution of the skin lesions and systemic symptoms.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Foot Diseases / pathology. Keratosis / pathology. Waldenstrom Macroglobulinemia / complications
  • [MeSH-minor] Chlorambucil / therapeutic use. Cyclophosphamide / therapeutic use. Diagnosis, Differential. Fluorescent Antibody Technique, Direct. Humans. Immunoglobulin M / blood. Male. Middle Aged. Treatment Outcome. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Foot Injuries and Disorders.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874364.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunoglobulin M; 18D0SL7309 / Chlorambucil; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


33. Dispenzieri A, Gertz MA: Treatment options for POEMS syndrome. Expert Opin Pharmacother; 2005 Jun;6(6):945-53
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment options for POEMS syndrome.
  • POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia.
  • Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman's disease, thrombocytosis, papilledema, peripheral oedema, pleural effusions, ascites, fingernail clubbing and white nails, is the first step in effectively managing the disease.
  • In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion.
  • Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion, and for those who have not demonstrated stabilisation of their disease 3-6 months after completing radiation therapy.
  • For those patients with diffuse disease, systemic therapy is indicated.
  • Useful approaches include therapy with corticosteroids, low dose alkylator therapy and high dose chemotherapy with peripheral blood stem cell transplant.
  • Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. POEMS Syndrome / drug therapy. POEMS Syndrome / surgery
  • [MeSH-minor] Humans. Plasmapheresis / trends. Stem Cell Transplantation / trends. Survival Rate

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952922.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 56
  •  go-up   go-down


34. Merlini G, Pozzi C: Mechanisms of renal damage in plasma cell dyscrasias: an overview. Contrib Nephrol; 2007;153:66-86
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanisms of renal damage in plasma cell dyscrasias: an overview.
  • The kidney is a target organ in plasma cell dyscrasias.
  • The kidney targeting is due to the concurrence of several factors such as the local catabolism of monoclonal LCs, specific interactions of the monoclonal proteins with tissue and cellular components, and local environmental conditions.
  • Glomerulopathic LCs interact with mesangial cells producing, through two distinct pathways, LC amyloidosis or monoclonal immunoglobulin deposition disease.
  • Tubulopathic LCs damage the proximal tubule causing Fanconi's syndrome or precipitate in the distal tubule determining the cast nephropathy.
  • In patients with known plasma cell dyscrasia, the recognition of these patterns of renal injury should lead to appropriate therapeutic intervention.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075224.001).
  • [ISSN] 0302-5144
  • [Journal-full-title] Contributions to nephrology
  • [ISO-abbreviation] Contrib Nephrol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains
  • [Number-of-references] 79
  •  go-up   go-down


35. Lommatzsch SE, Bellizzi AM, Cathro HP, Rosner MH: Acute renal failure caused by renal infiltration by hematolymphoid malignancy. Ann Diagn Pathol; 2006 Aug;10(4):230-4
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Renal involvement by a malignant infiltrative process is often suspected in patients with bilaterally enlarged kidneys and concurrent malignancies.
  • We present 2 cases in which ARF is attributable to malignant hematolymphoid infiltration.
  • The patient's renal function improved dramatically after the initiation of chemotherapy, clearly linking the development of ARF to the malignant process.
  • In the second case, infiltration of the kidneys by plasma cell leukemia resulted in dialysis dependence.
  • To our knowledge, this represents the first reported case of ARF attributable to documented renal infiltration by plasma cell leukemia.
  • A review of the potential causes of renal failure in hematolymphoid malignancy, focusing on the direct impact of the infiltrative process and on the spectrum of renal disease in plasma cell dyscrasia, is presented.
  • [MeSH-major] Acute Kidney Injury / etiology. Kidney / pathology. Leukemia, Plasma Cell / complications. Leukemic Infiltration. Lymphoma, Non-Hodgkin / complications
  • [MeSH-minor] Allopurinol / therapeutic use. Antimetabolites / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dexamethasone / therapeutic use. Female. Humans. Middle Aged. Thalidomide / therapeutic use. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844565.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites; 4Z8R6ORS6L / Thalidomide; 63CZ7GJN5I / Allopurinol; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


36. Koike H, Sobue G: Crow-Fukase syndrome. Neuropathology; 2000 Sep;20 Suppl:S69-72
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Crow-Fukase syndrome is a unique multisystem disorder that is also known as POEMS syndrome (an acronym for polyneuropathy, organomegaly, endocrinopathy, the presence of M-protein and skin change).
  • This syndrome is strongly associated with plasma cell dyscrasia.
  • M-protein, interleukin (IL)-1beta, IL-6 and tumor necrosis factor (TNF)-alpha are also considered to be involved in the pathogenesis.
  • Treatment consists of radiation and surgical resection of the myeloma, chemotherapy, and a high dose of intravenous immunoglobulin (IVIg).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11037192.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] AUSTRALIA
  • [Number-of-references] 21
  •  go-up   go-down


37. Raje N, Anderson KC: Multiple myeloma. Curr Treat Options Oncol; 2000 Apr;1(1):73-82
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is an incurable plasma cell dyscrasia that remains fatal.
  • Despite efforts over the past 3 to 4 decades, the median survival of patients with MM does not exceed 3 to 4 years.
  • Although patients receiving combination chemotherapy have higher response rates compared with those receiving oral melphalan and prednisolone, they have no survival advantage.
  • High-dose chemotherapy followed by autologous stem cell transplantation has documented benefit over conventional treatment and is currently the accepted mode of treatment for symptomatic MM.
  • Allogeneic transplantation is associated with high complete remission rates, but at the cost of high therapy-related mortality.
  • Maintenance treatment with interferon-alpha shows benefit, albeit in a small fraction of MM patients.
  • The use of bisphosphonates in patients with MM has clearly demonstrated benefit and reduced morbidity associated with bone disease.
  • All of these measures have improved remission rates and survival, but all patients with MM ultimately relapse and succumb to their disease.
  • Novel therapeutic strategies are therefore required to improve outcome of MM patients.
  • Immune-based strategies, including both adoptive immunotherapy and vaccinations, are currently being investigated in the preclinical and clinical setting, with the goal of enhancing autologous and allogeneic anti-MM immunity for therapeutic applications.
  • [MeSH-major] Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Bone Marrow Transplantation. Clinical Trials as Topic. Combined Modality Therapy. Humans. Interferons / therapeutic use. Prognosis. Thalidomide / therapeutic use. Transplantation, Autologous

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Environ Health. 1990 May-Jun;45(3):155-62 [2386420.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Br J Cancer. 1999 Feb;79(3-4):451-5 [10027312.001]
  • [Cites] Bone Marrow Transplant. 1998 Jan;21(2):133-40 [9489629.001]
  • [Cites] Bone Marrow Transplant. 1998 May;21(9):887-92 [9613780.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1575-84 [2131793.001]
  • [Cites] Ann Intern Med. 1986 Jul;105(1):8-11 [3717812.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 [7513432.001]
  • [Cites] Blood. 2000 Jan 1;95(1):7-11 [10607678.001]
  • [Cites] Bone Marrow Transplant. 1997 Sep;20(6):435-43 [9313875.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):153-60 [9136958.001]
  • [Cites] Amyloid. 2000 Jun;7(2):126-32 [10842716.001]
  • [Cites] Pathol Biol (Paris). 1999 Feb;47(2):172-7 [10192884.001]
  • [Cites] Blood. 1997 Feb 1;89(3):789-93 [9028309.001]
  • [Cites] Oncogene. 1999 Nov 18;18(48):6733-40 [10597281.001]
  • [Cites] Science. 1997 Jun 20;276(5320):1851-4 [9188529.001]
  • [Cites] Blood. 1983 Sep;62(3):572-7 [6882916.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1606-9 [10564693.001]
  • [Cites] Blood. 1996 Oct 1;88(7):2787-93 [8839877.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1312-22 [7751876.001]
  • [Cites] N Engl J Med. 1996 Feb 22;334(8):488-93 [8559201.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Blood. 1998 Jan 1;91(1):3-21 [9414264.001]
  • [Cites] Blood. 1999 May 1;93(9):3064-73 [10216103.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):879-82 [2571812.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • [Cites] Blood. 1999 Mar 1;93(5):1482-6 [10029574.001]
  • [Cites] Bone Marrow Transplant. 1999 Apr;23(7):675-80 [10218843.001]
  • [Cites] Blood. 1998 Feb 1;91(3):756-63 [9446633.001]
  • [Cites] Blood. 1992 Aug 15;80(4):887-90 [1498331.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5 Suppl 14):97-106 [10561024.001]
  • [Cites] Oncogene. 1997 Aug 14;15(7):837-43 [9266970.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4591-601 [9845525.001]
  • [Cites] Radiat Res. 1994 Feb;137(2 Suppl):S68-97 [8127953.001]
  • (PMID = 12057063.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4Z8R6ORS6L / Thalidomide; 9008-11-1 / Interferons
  • [Number-of-references] 39
  •  go-up   go-down


38. Goyal M, Mohammad N, Palanki SD, Vaniawala SN: Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature. Indian J Med Paediatr Oncol; 2010 Jul;31(3):96-100

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia with light chain secretion and multiple chromosomal abnormalities: How successfully treated? - A case report with review of literature.
  • Primary plasma cell leukemia is a rare form of plasma cell dyscrasia.
  • We present a case which had leukocytosis with numerous circulating plasma cells in the peripheral blood.
  • Radiography did not reveal any lytic lesions.
  • The patient was given chemotherapy and was subjected to autologous stem cell transplant, after which she is in complete remission till date.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Ann Hematol. 1992 Aug;65(2):88-90 [1511063.001]
  • [Cites] Am J Hematol. 2005 Apr;78(4):288-94 [15795922.001]
  • [Cites] Leuk Lymphoma. 2007 Jan;48(1):5-6 [17325841.001]
  • [Cites] Eur J Haematol Suppl. 1989;51:76-83 [2697596.001]
  • [Cites] Semin Hematol. 1987 Jul;24(3):202-8 [3116673.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):905-12 [6401225.001]
  • [Cites] Mayo Clin Proc. 2007 Oct;82(10):1179-84 [17908524.001]
  • [Cites] Leukemia. 2008 Jul;22(7):1343-53 [18509355.001]
  • [Cites] Leuk Lymphoma. 1996 Mar;21(1-2):25-30 [8907265.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] Eur J Cancer. 1993;29A(9):1269-73 [8343266.001]
  • (PMID = 21206718.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3009444
  • [Keywords] NOTNLM ; Flow cytometry / fluorescent in-situ hybridization / free light chains / primary plasma cell leukemia / transplant
  •  go-up   go-down


39. Batts ED, Sanchorawala V, Hegerfeldt Y, Lazarus HM: Azotemia associated with use of lenalidomide in plasma cell dyscrasias. Leuk Lymphoma; 2008 Jun;49(6):1108-15
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azotemia associated with use of lenalidomide in plasma cell dyscrasias.
  • Azotemia associated with the use of lenalidomide, a new and effective therapy for multiple myeloma, has not been reported in patients with multiple myeloma.
  • We describe five patients with plasma cell dyscrasias and renal insufficiency (AL amyloidosis, monoclonal gammopathy of undetermined significance with Fanconi syndrome, and multiple myeloma) treated with lenalidomide and dexamethasone who developed progressive azotemia.
  • Four patients required hemodialysis after exposure to lenalidomide; two previously were untreated for their plasma cell dyscrasia.
  • We conclude that azotemia is an uncommon, but serious, potential complication of lenalidomide therapy in plasma cell dyscrasias with associated renal insufficiency.
  • [MeSH-major] Acute Kidney Injury / etiology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Azotemia / chemically induced. Multiple Myeloma / drug therapy. Paraproteinemias / drug therapy. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Dexamethasone / therapeutic use. Disease Progression. Female. Humans. Male. Middle Aged. Paraproteins / metabolism. Renal Dialysis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18452093.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Paraproteins; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


40. Gillmore JD, Goodman HJ, Lachmann HJ, Offer M, Wechalekar AD, Joshi J, Pepys MB, Hawkins PN: Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood; 2006 Feb 01;107(3):1227-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis.
  • Extensive cardiac amyloid deposition in systemic AL amyloidosis is associated with a grave prognosis.
  • Heart transplantation is rarely performed because of the systemic and progressive nature of the disease.
  • Patients with severe cardiac amyloid infiltration are ineligible for the preferred treatment of melphalan chemotherapy with stem cell transplantation (SCT) rescue because of the high risk for treatment-related mortality.
  • At censor, 3 of 5 patients were well without evidence of intracardiac or extracardiac amyloid accumulation, and median overall survival by Kaplan-Meier estimate was not reached.
  • Two patients died of progressive amyloidosis 33 and 90 months after heart transplantation after relapse of their underlying plasma cell dyscrasia.
  • [MeSH-major] Amyloidosis / mortality. Cardiomyopathies / mortality. Heart Transplantation. Stem Cell Transplantation
  • [MeSH-minor] Adult. Amyloid / metabolism. Disease-Free Survival. Female. Humans. Male. Middle Aged. Transplantation, Autologous / mortality


41. Hussein MA: Thalidomide: present and future in multiple myeloma. Expert Rev Anticancer Ther; 2005 Feb;5(1):25-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma continues to be an incurable disease.
  • The understanding of the disease's pathophysiology has significantly improved over the past few years, partly due to the discovery of the role of immunomodulatory agents and the study of their mechanism of action.
  • Thalidomide, the first of the immunomodulatory family to be used in the management of multiple myeloma, proved not only to be effective in the treatment of multiple myeloma, but also instigated a wide range of in vitro and in vivo studies to define the pathophysiology of the plasma cell dyscrasia.
  • The attention thalidomide has received in the past and recent history has not been without a price.
  • The drug has a side-effect profile that, if managed appropriately, provides the most unique active molecule in the management of the disease, where it maintains the same response rate in newly diagnosed patients as in advanced relapsed/refractory multiple myeloma patients.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Multiple Myeloma / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Humans. Prognosis. Recurrence

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757435.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 58
  •  go-up   go-down


42. Nonami A, Miyamoto T, Kuroiwa M, Kunisaki Y, Kamezaki K, Takenaka K, Harada N, Teshima T, Harada M, Nagafuji K: Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling. Jpn J Clin Oncol; 2007 Dec;37(12):969-72
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.
  • Primary plasma cell leukaemia (PCL) is a rare, aggressive neoplasm of plasma cell dyscrasia.
  • Conventional chemotherapy is usually ineffective, with an overall survival of only 8 months.
  • Here, we describe a 42-year-old man with primary PCL, who was successfully treated with haploidentical (2-HLA loci mismatched) haematopoietic stem-cell transplantation (HSCT).
  • To overcome the human leukocyte antigen (HLA) disparity, in vivo T-cell purging by the pre-transplant administration of antithymocyte globulin followed by a conventional prophylactic treatment against graft-versus-host disease (GVHD) resulted in an avoidance of severe GVHD as well as infectious complications.
  • Haploidentical HSCT can be a potentially curative treatment for patients with primary PCL who do not have an HLA-identical donor.
  • [MeSH-major] Haplotypes. Hematopoietic Stem Cell Transplantation. Leukemia, Plasma Cell / surgery. Siblings. Transplantation Conditioning / methods
  • [MeSH-minor] Adult. Antilymphocyte Serum / administration & dosage. Bone Marrow Purging. Graft vs Host Disease / prevention & control. Humans. Immunosuppressive Agents / administration & dosage. Male. T-Lymphocytes. Transplantation, Homologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055567.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antilymphocyte Serum; 0 / Immunosuppressive Agents
  •  go-up   go-down


43. Hogan WJ, Lacy MQ, Wiseman GA, Fealey RD, Dispenzieri A, Gertz MA: Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation. Bone Marrow Transplant; 2001 Aug;28(3):305-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of POEMS syndrome with autologous hematopoietic progenitor cell transplantation.
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) is a plasma cell dyscrasia that differs substantially from classic multiple myeloma.
  • Current therapeutic approaches are frequently inadequate and leave many patients wheelchair-bound with significant deterioration in quality and length of life.
  • We present the case of a young man with progressive disease despite conventional therapeutic approaches.
  • We describe a novel approach to treatment with a bone-seeking radiopharmaceutical, samarium-153 ethylene diamine tetramethylene phosphonate ((153)Sm-EDTMP), followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell reconstitution.
  • An aggressive approach should be considered in patients with POEMS syndrome in whom standard therapeutic measures fail.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Organometallic Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. POEMS Syndrome / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents, Alkylating / administration & dosage. Dose-Response Relationship, Radiation. Drug Therapy, Combination. Graft Survival. Humans. Male. Melphalan / administration & dosage. Quality of Life. Radiopharmaceuticals / administration & dosage. Radiopharmaceuticals / pharmacokinetics. Radiopharmaceuticals / therapeutic use. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Bone Marrow Transplant. 2002 Jul;30(1):61-2 [12105781.001]
  • (PMID = 11536000.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Organometallic Compounds; 0 / Organophosphorus Compounds; 0 / Radiopharmaceuticals; 122575-21-7 / samarium ethylenediaminetetramethylenephosphonate; Q41OR9510P / Melphalan
  •  go-up   go-down


44. Shah AD, Watts AJ, Mehta AB, Wechalekar AD: An unusual case of transient dermatological reaction to bortezomib in AL amyloidosis. Int J Hematol; 2010 Jan;91(1):121-3
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic AL amyloidosis is a rare complication of monoclonal gammopathy or myeloma in which abnormally unstable free light chains cause fibrillary deposits in organs leading to multisystem disease.
  • The treatment of AL amyloidosis is directed at the underlying plasma cell dyscrasia and most regimes have been adapted from myeloma, but drug toxicity is more common in AL amyloidosis because of the more extensive nature of the disease.
  • We report a patient who developed asymptomatic purple discolouration of the veins of his left arm several days after receiving the infusion in his left hand, although the infusion itself had been uncomplicated with no extravasation.
  • There appears to be no indication for discontinuation of bortezomib treatment or dose alteration in such cases.
  • [MeSH-major] Amyloidosis / drug therapy. Boronic Acids / adverse effects. Drug Eruptions / pathology. Paraproteinemias / drug therapy. Protease Inhibitors / adverse effects. Pyrazines / adverse effects

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2003 Feb 15;101(4):1530-4 [12393500.001]
  • [Cites] Dermatology. 2008;216(2):156-8 [18216478.001]
  • [Cites] Nat Med. 2001 Dec;7(12 ):1291-7 [11726968.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14374-9 [12391322.001]
  • [Cites] Cancer Cell Int. 2005 Jun 01;5(1):18 [15929791.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):184-91 [16397231.001]
  • [Cites] Blood. 2005 Nov 1;106(9):3293-9 [15961519.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):667-75 [15613697.001]
  • [Cites] Haematologica. 2007 Oct;92(10):1351-8 [18024372.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):165-72 [15461622.001]
  • [Cites] Am J Hematol. 2007 Jun;82(6):502-3 [17301973.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2534 [15958809.001]
  • [Cites] Ann Hematol. 2007 Dec;86(12):923-4 [17641890.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Eur J Haematol. 2006 Mar;76(3):265-8 [16451401.001]
  • [Cites] Methods Mol Biol. 2009;512:169-207 [19347278.001]
  • (PMID = 20020230.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunoglobulin Light Chains; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


45. Zenhäusern R, Tobler A, Leoncini L, Hess OM, Ferrari P: Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. Ann Hematol; 2000 Sep;79(9):523-6
Hazardous Substances Data Bank. DIMETHYL SULFOXIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Amyloidosis (AL) is a rapidly fatal plasma cell dyscrasia causing progressive multiorgan failure.
  • Recently, substantial improvement of survival was reported following high-dose chemotherapy with peripheral blood stem cell (PBSC) rescue.
  • Immediately after the second infusion of the PBSCs, life-threatening cardiac arrhythmias occurred and, despite intensive treatment, the patient died less than 24 h later.
  • Given the poor prognosis of AL and the promising results of dose-intensive chemotherapy with autologous PBSC transplantation, careful patient selection and intensive monitoring are mandatory in order to further pursue this therapeutic approach.
  • [MeSH-major] Amyloidosis / therapy. Arrhythmias, Cardiac / chemically induced. Cardiomyopathies / therapy. Cryopreservation. Dimethyl Sulfoxide / adverse effects. Kidney Failure, Chronic / therapy. Stem Cells
  • [MeSH-minor] Fatal Outcome. Heart Arrest / etiology. Hematopoietic Stem Cell Transplantation. Humans. Male. Middle Aged


46. Gil L, Komarnicki M: [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis]. Pol Merkur Lekarski; 2009 Sep;27(159):181-4
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autologous stem cell transplantation in the treatment of primary systemic amyloidosis].
  • Primary systemic amyloidosis is a plasma cell dyscrasia resulting multiorgan failure and death.
  • The optimal treatment method is unknown.
  • Current status of therapy for primary amyloidosis based on has been publication analysis.
  • Treatment options for primary amyloidosis are similar to multiple myleoma therapy.
  • Treatment of primary amyloidosis should be based on risk factors analysis.
  • In selected patients high-dose therapy and autologous stem cell transplantation has been associated with higher response rate than standard chemotherapy However, autologous transplantation for primary amyloidosis remains controversial because of high treatment-related mortality.
  • Novel non-transplant methods for primary amyloidosis therapy are highly effective.
  • Early and detailed diagnosis and treatment based on risk factors can influence survival in group of patients with systemic primary amyloidosis.
  • [MeSH-major] Amyloidosis / therapy. Hematopoietic Stem Cell Transplantation
  • [MeSH-minor] Adult. Humans. Middle Aged. Myeloablative Agonists / therapeutic use. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19827724.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Editorial; English Abstract
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Myeloablative Agonists
  •  go-up   go-down


47. Arkenau HT, Widjaja A: [A rare case of cholestasis and macrohematuria in a 52-year-old patient]. Med Klin (Munich); 2002 Aug 15;97(8):480-3
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INVESTIGATIONS AND THERAPY: Due to the ultrasound and the CT scan of the abdomen, a kidney tumor was suspected.
  • A plasma cell dyscrasia of 15% was found by bone marrow biopsy.
  • Immunfixation showed an IgG-kappa light chain in plasma and urine.
  • Thus, the patient had a plasmacytoma Stage II associated with IgG-kappa light chain AL-amyloidosis which was treated by chemotherapy (melphalan and prednisolone).
  • CONCLUSION: This unusual case presents a cholestatic liver disease due to bile duct obstruction secondary to amyloid deposits.
  • Although AL-amyloidosis is easily diagnosed by certain criteria, the disease is often recognized too late with consequently poor prognosis.

  • Genetic Alliance. consumer health - Cholestasis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12229247.001).
  • [ISSN] 0723-5003
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Amyloid; 0 / Immunoglobulin G; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 0 / amyloid protein AL
  •  go-up   go-down


48. Gertz MA, Rajkumar SV: Primary systemic amyloidosis. Curr Treat Options Oncol; 2002 Jun;3(3):261-71
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary amyloidosis is a plasma cell dyscrasia in which insoluble immunoglobulin light chain fragments are produced and polymerize into fibrils that deposit extracellularly, causing visceral organ dysfunction and death.
  • The disorder is rare.
  • The least invasive source of tissue for amyloid detection is the subcutaneous fat.
  • Therapies used include oral melphalan/prednisone and high-dose corticosteroids.
  • High-dose chemotherapy followed by stem cell reconstitution seems to provide the highest reported response rates.
  • Transplant is associated with unique morbidities not seen in the transplantation of patients with other hematologic malignancies.
  • [MeSH-major] Amyloidosis / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Transplantation. Hematopoietic Stem Cell Transplantation. Humans. Melphalan / therapeutic use. Prednisone / therapeutic use. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 1995 Jan;32(1):45-59 [7878478.001]
  • [Cites] South Med J. 1993 May;86(5):568-9 [8488407.001]
  • [Cites] Am J Hematol. 1990 May;34(1):55-8 [2327405.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1202-7 [9110907.001]
  • [Cites] Bone Marrow Transplant. 1999 May;23(9):967-9 [10338056.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):149-81 [7542006.001]
  • [Cites] Circulation. 1991 Mar;83(3):808-16 [1999031.001]
  • [Cites] Semin Arthritis Rheum. 1994 Oct;24(2):124-38 [7839154.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):95-9 [1712547.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3350-6 [11454882.001]
  • [Cites] Blood. 1986 Jul;68(1):220-4 [3719098.001]
  • [Cites] Mayo Clin Proc. 1989 Dec;64(12):1505-19 [2513459.001]
  • [Cites] Medicine (Baltimore). 1986 May;65(3):173-9 [3702668.001]
  • [Cites] Am J Hematol. 1994 Feb;45(2):171-6 [8141123.001]
  • [Cites] Gut. 1994 Sep;35(9):1322-5 [7959246.001]
  • [Cites] Br J Haematol. 1997 Nov;99(2):245-56 [9375734.001]
  • [Cites] Am J Cardiol. 1995 Oct 1;76(10 ):739-41 [7572642.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1996 Jun;60(6):655-60 [8648333.001]
  • [Cites] J Lab Clin Med. 1991 Jul;118(1):33-9 [1906082.001]
  • [Cites] J Am Coll Cardiol. 1996 Sep;28(3):658-64 [8772753.001]
  • [Cites] Am J Cardiol. 1997 Nov 1;80(9):1242-5 [9359565.001]
  • [Cites] Biochem J. 2000 Oct 1;351(Pt 1):273-9 [10998371.001]
  • [Cites] Am J Med. 1998 Mar;104(3):232-7 [9552085.001]
  • [Cites] Medicine (Baltimore). 1993 Jan;72(1):45-63; discussion 63-5 [8426537.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1501-5 [9554527.001]
  • [Cites] Nephrol Dial Transplant. 1996;11 Suppl 9:63-8 [9050037.001]
  • [Cites] Mayo Clin Proc. 1984 Sep;59(9):589-97 [6471919.001]
  • [Cites] Am J Med. 1996 Mar;100(3):290-8 [8629674.001]
  • [Cites] J Intern Med. 1992 Dec;232(6):517-8 [1474356.001]
  • [Cites] Bone Marrow Transplant. 2000 Mar;25(5):465-70 [10713619.001]
  • [Cites] Blood. 1995 Aug 1;86(3):855-61 [7620181.001]
  • [Cites] Am J Hematol. 1993 Oct;44(2):125-8 [8266917.001]
  • [Cites] Arch Dermatol. 1998 May;134(5):643-5 [9606347.001]
  • [Cites] Arch Intern Med. 1990 Mar;150(3):629-33 [2310282.001]
  • [Cites] Blood. 1991 Jan 15;77(2):257-62 [1985692.001]
  • [Cites] Int J Dermatol. 1996 Aug;35(8):553-7 [8854150.001]
  • [Cites] Leuk Lymphoma. 1997 Oct;27(3-4):351-6 [9402333.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1817-22 [1558973.001]
  • [Cites] Arthritis Rheum. 1993 May;36(5):691-7 [7683882.001]
  • [Cites] J Rheumatol. 1996 Jan;23(1):189-90 [8838533.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):763-70 [8616770.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):262-7 [10458241.001]
  • [Cites] Hum Pathol. 1988 Nov;19(11):1255-72 [3141259.001]
  • [Cites] Scand J Rheumatol. 1995;24(6):327-9 [8610214.001]
  • [Cites] Arthritis Rheum. 1993 Mar;36(3):422-5 [8452587.001]
  • [Cites] Am J Cardiol. 1997 Feb 15;79(4):532-5 [9052371.001]
  • [Cites] Am J Pathol. 2000 Jun;156(6):1919-25 [10854215.001]
  • [Cites] Am J Pathol. 1992 Mar;140(3):629-37 [1546744.001]
  • [Cites] J Cardiol. 1991;21(2):391-401 [1841926.001]
  • (PMID = 12057072.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  • [Number-of-references] 50
  •  go-up   go-down


49. Pentenero M, Davico Bonino L, Tomasini C, Conrotto D, Gandolfo S: Localized oral amyloidosis of the palate. Amyloid; 2006 Mar;13(1):42-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Amyloidosis is a rare disease with multifactorial pathogenesis.
  • CONCLUSIONS: The presence of systemic amyloidosis or underlying plasma cell dyscrasia have to be ruled out in patients presenting with a diagnosis of amyloidosis of the oral mucosa.
  • If a primary localized amyloidosis is proven, the surgical therapy may be useful to eliminate a functional impairment.
  • [MeSH-minor] Aged. Antifungal Agents / therapeutic use. Candidiasis / drug therapy. Candidiasis / pathology. Female. Humans. Mouth Mucosa / microbiology. Mouth Mucosa / pathology

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16690500.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents
  • [Number-of-references] 29
  •  go-up   go-down


50. Orlowski RZ, Zeger EL: Targeting the proteasome as a therapeutic strategy against haematological malignancies. Expert Opin Investig Drugs; 2006 Feb;15(2):117-30
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeting the proteasome as a therapeutic strategy against haematological malignancies.
  • Inhibition of the proteasome induces beneficial antitumour effects by blocking cell-cycle progression, inducing apoptosis and suppressing angiogenesis.
  • Testing is ongoing to determine bortezomib's role in front-line therapy of this plasma cell dyscrasia, as well as in non-Hodgkin's lymphoma, in which encouraging single-agent activity has been seen.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Drug Delivery Systems / methods. Hematologic Neoplasms / drug therapy. Hematologic Neoplasms / enzymology. Protease Inhibitors / administration & dosage. Proteasome Inhibitors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16433592.001).
  • [ISSN] 1744-7658
  • [Journal-full-title] Expert opinion on investigational drugs
  • [ISO-abbreviation] Expert Opin Investig Drugs
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102278; United States / NHLBI NIH HHS / HL / T32 HL 007149
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Proteasome Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 71
  •  go-up   go-down


51. Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A: Localized AL amyloidosis of the colon: an unrecognized entity. Amyloid; 2003 Mar;10(1):36-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Virtually all patients who present with rectal bleeding and amyloid of the colon have evidence of systemic amyloidosis and require therapy.
  • The small subset of patients with amyloidosis localized to the colon must be recognized and treatment avoided.
  • These patients had no evidence of a plasma cell dyscrasia and received no chemotherapy to prevent deposition of amyloid.
  • It is important to recognize this rare subset and avoid treatment with alkylating agents or high-dose therapy followed by autologous stem cell transplantation.
  • Alkylating agent therapy may be associated with myelodysplasia or acute leukemia.
  • In addition, the cost, inconvenience, and morbidity of therapy are avoided by observation.
  • Patients who present with rectal bleeding and a subsequent diagnosis of amyloidosis of the colon likely will be subjected to chemotherapy or transplantation.
  • Such patients must be recognized and treatment avoided if there is no evidence of systemic amyloidosis because they remain stable for many years.

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12762141.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA62242
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


52. Dezube BJ, Aboulafia DM, Pantanowitz L: Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma. AIDS Read; 2004 Jul;14(7):372-4, 377-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell disorders in HIV-infected patients: from benign gammopathy to multiple myeloma.
  • Plasma cell disorders are not uncommonly reported in young patients with HIV infection.
  • These disorders range from benign polyclonal hypergammaglobulinemia to indeterminate monoclonal gammopathy of unknown significance (MGUS) to malignant dyscrasias, including multiple myeloma and plasma cell leukemia.
  • Hypergammaglobulinemia and oligoclonal banding had been the most frequently reported disorders in the pre-HAART era.
  • Many of these HIV-infected patients had been treated with alkylator-based regimens, and these reports predate the current widespread use of thalidomide-dexamethasone combination treatment in multiple myeloma.
  • Although the optimal therapy for an HIV-infected person might with plasma cell dyscrasia is yet to be defined, in the current era of HAART the otherwise healthy HIV-infected patient might be tested like an HIV-negative person.
  • Consequently, treatment with immunomodulatory agents (eg, thalidomide) and proteasome inhibitors (eg, bortezomib) may also be worth considering.
  • High-dose chemotherapy with an autologous peripheral blood stem cell transplant is increasingly being considered as consolidation therapy in the younger non-HIV-infected myeloma patient.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Stem Cell Transplantation. Thalidomide / therapeutic use


53. Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC: Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood; 2001 Mar 15;97(6):1885-7
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
  • Ten factor X-deficient patients received high-dose melphalan chemotherapy followed by autologous stem cell transplantation.
  • Of 7 patients alive 1 year after treatment, 4 had a complete hematologic response, and all 4 experienced improvement in their factor X levels.
  • Thus, aggressive treatment of the underlying plasma cell dyscrasia in AL amyloidosis can lead to the amelioration of amyloid-related factor X deficiency.
  • [MeSH-minor] Amyloid. Antineoplastic Agents / therapeutic use. Blood Coagulation Tests. Follow-Up Studies. Hematopoietic Stem Cell Transplantation. Hemorrhage / etiology. Incidence. Melphalan / administration & dosage. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11238135.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R-001346
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antineoplastic Agents; 0 / amyloid protein AR, human; Q41OR9510P / Melphalan
  •  go-up   go-down


54. Kuwabara S, Misawa S, Kanai K, Suzuki Y, Kikkawa Y, Sawai S, Hattori T, Nishimura M, Nakaseko C: Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology; 2008 Nov 18;71(21):1691-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome.
  • BACKGROUND: Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome is a rare multisystem disorder associated with plasma cell dyscrasia.
  • There is increasing evidence that high-dose chemotherapy with autologous peripheral blood stem cell transplantation (Auto-PBSCT) is an efficacious treatment.
  • OBJECTIVE: To elucidate the extent and time course of neurologic improvement after Auto-PBSCT in patients with POEMS syndrome.
  • Nerve conduction studies showed significant increases in conduction velocities and amplitudes within 6 months of treatment.
  • CONCLUSION: Autologous peripheral blood stem cell transplantation results in obvious neurologic improvement within 6 months, presumably by extensive axonal regeneration and remyelination.
  • This therapy could be considered as a first line treatment for patients with polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes syndrome with younger onset even if they are tetraplegic.
  • [MeSH-major] Hand Strength / physiology. Neural Conduction / physiology. POEMS Syndrome / therapy. Peripheral Blood Stem Cell Transplantation / methods
  • [MeSH-minor] Action Potentials / physiology. Adult. Combined Modality Therapy. Drug Therapy / methods. Female. Follow-Up Studies. Humans. Male. Median Nerve / physiopathology. Middle Aged. Retrospective Studies. Time Factors. Transplantation, Autologous. Treatment Outcome. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2009 Oct 6;73(14):1165; author reply 1165-6 [19805738.001]
  • [CommentIn] Neurology. 2008 Nov 18;71(21):1658-9 [18832139.001]
  • (PMID = 18832140.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


55. Kelly JJ: Neurologic complications of primary systemic amyloidosis. Rev Neurol Dis; 2006;3(4):173-81
MedlinePlus Health Information. consumer health - Amyloidosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The deposits in primary systemic amyloidosis are derived from monoclonal serum proteins in plasma cell dyscrasia, which are degraded locally in tissues and deposited in insoluble sheets that damage organs.
  • Symptoms of the disorder include neuropathy, myopathy, and cardiac or renal insufficiency; there is often multiple-organ involvement.
  • Differential difficulties exist in diagnosing the disorder, and familial amyloid polyneuropathy directly mimics the disease.
  • Diagnostic tools include electromyography, laboratory testing for abnormalities in serum and urine, and histological investigation of appropriate tissue.
  • However, melphalan and prednisone treatment for at least 1 year has resulted in increased survival rates.
  • There have also been reports of benefit from high-dose chemotherapy followed by peripheral blood stem cell transplantation.
  • Without early therapy, however, the disease has a dismal prognosis, and peripheral neuropathy usually persists or worsens despite therapy and improvement in other organs.

  • Genetic Alliance. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17224900.001).
  • [ISSN] 1545-2913
  • [Journal-full-title] Reviews in neurological diseases
  • [ISO-abbreviation] Rev Neurol Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 57
  •  go-up   go-down


56. Dispenzieri A, Kyle RA, Lacy MQ, Therneau TM, Larson DR, Plevak MF, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA, Zeldenrust SR, Snow DS, Hayman SR, Litzow MR, Gastineau DA, Tefferi A, Inwards DJ, Micallef IN, Ansell SM, Porrata LF, Elliott MA, Gertz MA: Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood; 2004 May 15;103(10):3960-3
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study.
  • Primary systemic amyloidosis (AL) is a plasma cell dyscrasia resulting in multisystem failure and death.
  • High-dose chemotherapy with peripheral blood stem cell transplantation (PBSCT) has been associated with higher response rates and seemingly higher overall survival than standard chemotherapy.
  • We performed a case-match-control study comparing overall survival of 63 AL patients undergoing transplantation with 63 patients not undergoing transplantation.
  • Matching criteria included age, sex, time to presentation, left ventricular ejection fraction, serum creatinine, septal thickness, nerve involvement, 24-hour urine protein, and serum alkaline phosphatase.
  • [MeSH-major] Amyloidosis / therapy. Peripheral Blood Stem Cell Transplantation / mortality
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Female. Humans. Male. Middle Aged. Paraproteinemias / mortality. Paraproteinemias / therapy. Proportional Hazards Models. Retrospective Studies. Survival Analysis. Survival Rate

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2004 Nov 1;104(9):2990-1; author reply 2992-4 [15498863.001]
  • [CommentIn] Blood. 2004 Nov 1;104(9):2991; author reply 2992-4 [15498864.001]
  • (PMID = 14739213.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 62242; United States / NCI NIH HHS / CA / CA 91561
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


57. Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC: Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant; 2007 Sep;40(6):557-62
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
  • Clinical outcomes of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation (HDM/SCT) are tightly linked to the achievement of a hematologic complete response (HCR).
  • We conducted a prospective trial to determine whether a second cycle of HDM/SCT could induce HCR in patients in whom the plasma cell dyscrasia persisted following initial treatment with HDM/SCT.
  • Of the 53 patients continuing in this study, four died within 100 days of treatment (8%), and 27 (55%) achieved an HCR at 6 months after the first cycle of HDM/SCT.
  • Of the 22 patients who did not achieve an HCR after initial treatment, 17 received a second HDM/SCT, 1 died within 100 days of treatment (6%), while 5 (31%) achieved an HCR.
  • The median survival for all patients enrolled on the trial has not yet been reached.
  • [MeSH-major] Amyloidosis / drug therapy. Antineoplastic Agents, Alkylating / administration & dosage. Hematopoietic Stem Cell Transplantation. Immunoglobulin Light Chains. Melphalan / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Patient Dropouts. Prospective Studies. Survival Rate. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Bone Marrow Transplant. 2007 Sep;40(6):607
  • (PMID = 17589534.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL68705
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  •  go-up   go-down


58. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA: Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer; 2004 Aug 1;101(3):558-66
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease.
  • BACKGROUND: Venous thromboembolic disease (VTD) is a recently recognized complication of thalidomide in combination therapy for patients with multiple myeloma (MM).
  • The authors assessed the frequency of VTD and its risk factors in 612 consecutive patients with plasma cell dyscrasia (PCD) who were evaluated and followed from 1991 to 2001.
  • The type of the treatment regimen did not appear to correlate with the development of VTD.
  • [MeSH-minor] Adult. Age Distribution. Aged. Aged, 80 and over. Case-Control Studies. Comorbidity. Female. Humans. Incidence. Male. Middle Aged. Multivariate Analysis. Paraproteinemias / diagnosis. Paraproteinemias / drug therapy. Paraproteinemias / epidemiology. Probability. Prognosis. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis. Thalidomide / adverse effects. Thalidomide / therapeutic use

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15274069.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


59. Tzankov A, Pölzl G, Mairinger T: Congo red-positive cardiac kappa-AL amyloidosis in plasmacytoma -- case report and review of the literature. Acta Med Austriaca; 2003;30(1):29-32
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congestive heart failure had gradually developed since that time.
  • In 2001 echocardiography revealed a pronounced thickening of the left ventricular wall with systolic and diastolic dysfunction.
  • Cyclophosphamide/prednisolone chemotherapy regimen led to complete haematological remission.
  • Cardiac transplantation, combined with autologous peripheral blood stem cell graft, was considered as the next therapeutic step, but the patient died while on the waiting list for transplantation.
  • The present case is remarkable as it demonstrates that carpal tunnel syndrome and congestive heart failure could be symptoms of plasma cell dyscrasia-associated amyloidoses.
  • [MeSH-minor] Adult. Amyloid / analysis. Antineoplastic Agents / therapeutic use. Bone Marrow / pathology. Cardiomegaly / complications. Cardiomegaly / pathology. Congo Red. Cyclophosphamide / therapeutic use. Fatal Outcome. Female. Humans. Immunoglobulin Light Chains / analysis. Immunoglobulin kappa-Chains / analysis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12558564.001).
  • [ISSN] 0303-8173
  • [Journal-full-title] Acta medica Austriaca
  • [ISO-abbreviation] Acta Med. Austriaca
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antineoplastic Agents; 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains; 3U05FHG59S / Congo Red; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


60. Sanders PW: Management of paraproteinemic renal disease. Curr Opin Nephrol Hypertens; 2005 Mar;14(2):97-103
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of paraproteinemic renal disease.
  • PURPOSE OF REVIEW: Paraproteinemic renal diseases comprise a group of renal disorders that are difficult to manage, in part because of subtleties in the clinical presentation and confusion regarding diagnosis and appropriate therapy.
  • Often, nephrologists make the diagnosis of the underlying plasma cell dyscrasia following renal biopsy.
  • This review seeks to provide a greater understanding of the mechanism of disease and recent approaches to the management of patients who have AL-amyloidosis, monoclonal light-chain and light and heavy-chain deposition disease [termed ML(H)CDD], and cast nephropathy.
  • This review seeks to provide a greater understanding of the mechanism of disease and recent approaches to the management of these patients.
  • Therapy aimed at eradicating the offending clone of plasma cells that secrete the monoclonal light chain should be beneficial, but this hypothesis lacks confirmation.
  • Four nonrandomized studies have now demonstrated clinical benefit, including return of renal function, of high-dose chemotherapy with autologous stem cell transplantation (HDT/SCT) in the treatment of patients who have AL-amyloidosis or ML(H)CDD.
  • SUMMARY: While randomized trials are lacking, the data support the clinical efficacy of more aggressive treatments designed to reduce the plasma cell clone responsible for these renal disorders.
  • [MeSH-major] Kidney Diseases / diagnosis. Kidney Diseases / therapy. Paraproteinemias / diagnosis. Paraproteinemias / therapy

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15687834.001).
  • [ISSN] 1062-4821
  • [Journal-full-title] Current opinion in nephrology and hypertension
  • [ISO-abbreviation] Curr. Opin. Nephrol. Hypertens.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


61. Kuwabara S, Misawa S, Kanai K, Sawai S, Hattori T, Nishimura M, Nakaseko C: Thalidomide reduces serum VEGF levels and improves peripheral neuropathy in POEMS syndrome. J Neurol Neurosurg Psychiatry; 2008 Nov;79(11):1255-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Polyneuropathy, organomegaly, endocrinopathy, M-protein and skin changes (POEMS) syndrome is a rare multi-system disorder associated with plasma-cell dyscrasia.
  • Several case series and reports have suggested that high-dose chemotherapy with autologous peripheral blood stem-cell transplantation is efficacious treatment, but this transplantation is not indicated for elderly patients and patients with renal failure.
  • OBJECTIVE: To investigate the effects of thalidomide treatment for POEMS syndrome.
  • METHODS: Nine patients, who were not indicated for high-dose chemotherapy, were treated with thalidomide.
  • CONCLUSION: Thalidomide treatment should be further studied as a treatment for POEMS syndrome, particularly for patients who are not indicated for transplantation therapy.
  • [MeSH-major] Angiogenesis Inhibitors / pharmacology. Angiogenesis Inhibitors / therapeutic use. POEMS Syndrome / blood. POEMS Syndrome / drug therapy. Peripheral Nervous System Diseases / drug therapy. Peripheral Nervous System Diseases / physiopathology. Thalidomide / pharmacology. Thalidomide / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anti-Inflammatory Agents / therapeutic use. Dexamethasone / therapeutic use. Drug Administration Schedule. Drug Therapy, Combination. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - POEMS syndrome.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469028.001).
  • [ISSN] 1468-330X
  • [Journal-full-title] Journal of neurology, neurosurgery, and psychiatry
  • [ISO-abbreviation] J. Neurol. Neurosurg. Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Anti-Inflammatory Agents; 0 / Vascular Endothelial Growth Factor A; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


62. Greco C, Alvino S, Del Monte G, Venturo I, Lopez M: Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias. J Exp Clin Cancer Res; 2003 Dec;22(4):607-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential usefulness of serum p53 for laboratory management of plasma cell dyscrasias.
  • We measured the serum levels of p53 mutant protein (p53M-ELISA) in 65 patients with plasma cell dyscrasia (PCD) and compared them with some conventional laboratory variables.
  • Our aim was to assess, for the first time, the potential of this parameter as a new marker for laboratory management of PCD.
  • MM patients, with no prior chemotherapy consecutively entered this study.
  • They were treated with standard regimens of Melphalan and Prednisone (MP) and were analyzed for serum p53M level from the time of diagnosis to response to therapy or death.
  • A subgroup of nine patients was regularly monitored for changes occurring in p53M levels during MP therapy.
  • Significantly higher p53M levels were shown by MM patients refractory to chemotherapy than by responding patients (0.38 ng/ml vs 0.22 ng/ml, p = 0.05).
  • The measurement of serum p53M in the nine patients during the course of chemotherapy correlated with disease progression or response to therapy.
  • [MeSH-major] Paraproteinemias / blood. Paraproteinemias / drug therapy. Tumor Suppressor Protein p53 / blood
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Melphalan / therapeutic use. Middle Aged. Multiple Myeloma / blood. Multiple Myeloma / drug therapy. Prednisone / therapeutic use. Prognosis

  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15053303.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


63. Saleh S, Ghodsian S, Yakimova V, Henderson J, Sharma OP: Effectiveness of infliximab in treating selected patients with sarcoidosis. Respir Med; 2006 Nov;100(11):2053-9
Hazardous Substances Data Bank. Infliximab .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effectiveness of infliximab (Remicade) in the treatment of patients with sarcoidosis who either do not respond to corticosteroids and other conventional drugs or develop unacceptable side effects to these drugs.
  • PATIENTS: Twelve biopsy-proven sarcoidosis patients, nine women and three men ranging from 45 to 70 years of age with chronic multisystem sarcoidosis refractory to corticosteroids or alternative treatment.
  • One patient had a mild allergic drug reaction that responded to antihistamine.
  • One patient, after 3 months of stopping infliximab treatment, died of a ruptured blood vessel in the abdomen.
  • At autopsy a plasma cell dyscrasia was found.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Sarcoidosis / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Female. Humans. Infliximab. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Sarcoidosis.
  • MedlinePlus Health Information. consumer health - Sarcoidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16935484.001).
  • [ISSN] 0954-6111
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; B72HH48FLU / Infliximab
  •  go-up   go-down


64. Ishikawa H, Tsuyama N, Mahmoud MS, Fujii R, Abroun S, Liu S, Li FJ, Kawano MM: CD19 expression and growth inhibition of tumours in human multiple myeloma. Leuk Lymphoma; 2002 Mar;43(3):613-6
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is a proliferative disorder of monoclonal plasma cells which accumulate in human bone marrow (BM).
  • CD19 is a hallmark differentiation antigen of the B cell lineage and positively regulates antigen receptor signal transduction in mature B cells.
  • We have previously shown that malignant plasma cells (myeloma cells) isolated from the MM patients lack the CD19 expression, while non-malignant plasma cells isolated from the healthy donors do express the CD19 antigens.
  • It is also intriguing that there exists both CD19- and CD19+ plasma cells in some cases in pre-myeloma states including monoclonal gammopathy of undetermined significance (MGUS).
  • It indicates that MGUS is usually composed of phenotypically non-malignant (CD19+) and malignant (CD19-) plasma cells.
  • Furthermore, we recently demonstrate that, expression of the CD19 gene markedly inhibits the proliferation of human myeloma cell lines in vitro, and exhibits the reduced tumorigenicity in vivo and no anchorage-independent growth in vitro of a tumorigenic myeloma cell line.
  • This inhibitory effect might result from the CD19-mediated intracellular signals because it is not observed in cells expressing the mutant CD19, which lacks the cytoplasmic domain.
  • In this review, we suggest that loss of CD19 in MM could contribute to the proliferative advantage of the malignant plasma cell clones in this disease.
  • Furthermore, we propose the usefulness of the phenotypic analysis of plasma cells in human plasma cell dyscrasia as a new diagnostic tool, and the CD19 gene as a potential target for the gene therapy in MM.
  • [MeSH-minor] Cell Division / drug effects. Humans. Plasma Cells / cytology. Plasma Cells / metabolism. Plasma Cells / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002767.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD19
  • [Number-of-references] 27
  •  go-up   go-down


65. Colović M, Janković G, Suvajdzić N, Milić N, Dordević V, Janković S: Thirty patients with primary plasma cell leukemia: a single center experience. Med Oncol; 2008;25(2):154-60
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thirty patients with primary plasma cell leukemia: a single center experience.
  • The primary plasma cell leukemia (PCL) is a rare aggressive plasma cell dyscrasia.
  • All patients had anemia, thrombocytopenia, circulating plasma cells (median count 4 x 10(9)/l), and in 18/30 patients hypercalcemia was found.
  • The plasma cells were CD138+ and CD38+ (9/9), CD20+ (1/9), and CD10+ (1/9) with cytoplasmic positivity for light chains (9/9).
  • Treatment modalities had no impact on survival (median 4.5 months).
  • [MeSH-major] Leukemia, Plasma Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged. Prognosis. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2003 Jun;121(5):749-57 [12780789.001]
  • [Cites] Blood. 1978 Oct;52(4):839-45 [687831.001]
  • [Cites] Cancer Genet Cytogenet. 1994 Jun;74(2):109-14 [8019953.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1032-7 [9920853.001]
  • [Cites] Curr Treat Options Oncol. 2001 Jun;2(3):205-16 [12057120.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4269-78 [9834233.001]
  • [Cites] Leukemia. 2005 Apr;19(4):659-63 [15716988.001]
  • [Cites] Leukemia. 1998 Jun;12(6):960-9 [9639426.001]
  • [Cites] Blood. 2001 Feb 1;97(3):822-5 [11157506.001]
  • [Cites] J Maine Med Assoc. 1977 Oct;68(10):350-1 [908884.001]
  • [Cites] Blood. 1997 Jul 15;90(2):526-34 [9226151.001]
  • [Cites] Leukemia. 1996 May;10(5):877-95 [8656686.001]
  • [Cites] Br J Haematol. 1994 Dec;88(4):754-9 [7819100.001]
  • [Cites] Blood. 1982 Oct;60(4):851-5 [7115956.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Am J Med. 1987 Dec;83(6):1062-8 [3503574.001]
  • [Cites] Arch Intern Med. 1974 May;133(5):813-8 [4821776.001]
  • [Cites] N Engl J Med. 1984 May 24;310(21):1353-6 [6546971.001]
  • (PMID = 18488157.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


66. Dispenzieri A: POEMS syndrome. Blood Rev; 2007 Nov;21(6):285-99
Genetic Alliance. consumer health - POEMS syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • POEMS syndrome is a rare paraneoplastic syndrome secondary to a plasma cell dyscrasia.
  • Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, papilledema, extravascular volume overload (peripheral edema, pleural effusions, ascites), sclerotic bone lesions, thrombocytosis, Castleman disease is the first step in effectively managing the disease.
  • In patients with a dominant sclerotic plasmacytoma, first line therapy should include radiation to the lesion.
  • Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion and for those who have not demonstrated stabilization of their disease 3 to 6 months after completing radiation therapy.
  • For those patients with diffuse disease, systemic therapy is indicated.
  • Useful approaches include therapy with corticosteroids, low dose alkylator therapy, and high dose chemotherapy with peripheral blood stem cell transplant.
  • Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.
  • The role of anti-VEGF therapies, immune modulatory drugs, and proteasome inhibitors has not yet been defined, but drugs with known high rates of treatment related neuropathy should not be considered as first line therapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant / methods. Giant Lymph Node Hyperplasia / complications. Hematopoietic Stem Cell Transplantation / methods. Humans. Respiratory Function Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17850941.001).
  • [ISSN] 0268-960X
  • [Journal-full-title] Blood reviews
  • [ISO-abbreviation] Blood Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  • [Number-of-references] 165
  •  go-up   go-down


67. Dispenzieri A, Gertz MA: Treatment of POEMS syndrome. Curr Treat Options Oncol; 2004 Jun;5(3):249-57
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of POEMS syndrome.
  • POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome is a rare multisystemic paraneoplastic syndrome driven by an underlying plasma cell dyscrasia.
  • Recognition of the complex of a combination of peripheral neuropathy, organomegaly, endocrinopathy, monoclonal plasmaproliferative disorder, skin changes, sclerotic bone lesions, Castleman disease, thrombocytosis, papilledema, peripheral edema, pleural effusions, ascites, fingernail clubbing, and white nails is the first step in effectively managing the disease.
  • Once a patient has been completely evaluated, each component of the disease should be addressed, while finalizing a treatment plan for the underlying plasma cell proliferative disorder.
  • In patients with a dominant sclerotic plasmacytoma, first-line therapy should include radiation to the lesion.
  • Retrospective analysis and personal experience would dictate that systemic therapy be considered for patients with diffuse sclerotic lesions or absence of any bone lesion and for patients who have not demonstrated stabilization of their disease 3 to 6 months after completing radiation therapy.
  • Treatments with demonstrated benefit include corticosteroids, low-dose alkylator therapy, and high-dose chemotherapy with peripheral blood stem cell transplant.
  • Until the pathogenesis is fully understood, these are the mainstays of treatment for patients with POEMS syndrome.
  • [MeSH-major] POEMS Syndrome / therapy
  • [MeSH-minor] Combined Modality Therapy. Decision Trees. Humans

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Ophthalmol. 1998 Sep;126(3):452-4 [9744383.001]
  • [Cites] Muscle Nerve. 1998 Nov;21(11):1390-7 [9771661.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2496-506 [12456500.001]
  • [Cites] Neurology. 1988 Apr;38(4):614-6 [2832785.001]
  • [Cites] Medicine (Baltimore). 1980 Jul;59(4):311-22 [6248720.001]
  • [Cites] Arch Phys Med Rehabil. 1995 Jul;76(7):692-4 [7605193.001]
  • [Cites] Clin Neurol Neurosurg. 1991;93(2):165-70 [1652401.001]
  • [Cites] Acta Med Scand. 1980;208(1-2):137-44 [6254342.001]
  • [Cites] Jpn J Clin Oncol. 1983 Sep;13(3):543-55 [6315993.001]
  • [Cites] Neurol Res. 1994 Dec;16(6):477-80 [7708142.001]
  • [Cites] Medicine (Baltimore). 1980 Jul;59(4):301-10 [6248719.001]
  • [Cites] Clin Neurol Neurosurg. 1992;94(1):65-8 [1321702.001]
  • [Cites] Intern Med. 1996 Aug;35(8):660-2 [8894744.001]
  • [Cites] J Clin Apher. 1985;2(3):253-7 [2993255.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1989 Feb;52(2):286 [2703847.001]
  • [Cites] Muscle Nerve. 2000 Jul;23(7):1051-6 [10882999.001]
  • [Cites] Muscle Nerve. 1997 Aug;20(8):1035-7 [9236797.001]
  • [Cites] Bone Marrow Transplant. 2001 Aug;28(3):305-9 [11536000.001]
  • [Cites] Zhonghua Yi Xue Za Zhi (Taipei). 1996 Nov;58(5):366-9 [9037854.001]
  • [Cites] J Neurol. 1995 Jul;242(7):482-3 [7595683.001]
  • [Cites] Neurology. 1984 Jun;34(6):712-20 [6539431.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):821-4 [12181052.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Jan;55(1):71-2 [1548501.001]
  • [Cites] Bone Marrow Transplant. 2002 Sep;30(6):401-4 [12235526.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Nov;6(11):1497-501 [6780494.001]
  • [Cites] Br J Haematol. 2001 Nov;115(2):373-5 [11703338.001]
  • [Cites] Ann Ital Med Int. 1991 Oct-Dec;6(4):416-9 [1804287.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Blood. 2002 Oct 1;100(7):2679-80 [12360984.001]
  • [Cites] Lancet. 1996 Mar 9;347(9002):701-2 [8596425.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(1):3-9 [3085338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Jan;16(1):43-8 [2912957.001]
  • [Cites] Blood. 2002 Apr 15;99(8):3057-9 [11929800.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1967 Oct;30(5):432-42 [6075207.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1997 Sep;63(3):385-7 [9328260.001]
  • [Cites] Arch Neurol. 1972 Dec;27(6):507-11 [4343458.001]
  • [Cites] Acta Haematol. 1995;94(2):90-4 [7484019.001]
  • [Cites] Scott Med J. 1989 Oct;34(5):520-2 [2555917.001]
  • [Cites] J Neurol Sci. 1998 Jun 11;158(1):113-7 [9667789.001]
  • [Cites] Neurology. 1977 Jul;27(7):675-81 [559975.001]
  • [Cites] Fukuoka Igaku Zasshi. 1992 Feb;83(2):112-20 [1592333.001]
  • [Cites] Rinsho Shinkeigaku. 1993 Jan;33(1):56-60 [8334776.001]
  • [Cites] Arthritis Rheum. 1996 Aug;39(8):1423-6 [8702454.001]
  • [Cites] Bone Marrow Transplant. 2002 Jul;30(1):61-2 [12105781.001]
  • [Cites] Am J Med. 1994 Dec;97(6):543-53 [7985714.001]
  • (PMID = 15115653.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 46
  •  go-up   go-down


68. Sanchorawala V, Wright DG, Rosenzweig M, Finn KT, Fennessey S, Zeldis JB, Skinner M, Seldin DC: Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood; 2007 Jan 15;109(2):492-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.
  • In immunoglobulin light chain (AL) amyloidosis, amyloid fibril deposits derived from immunoglobulin light chains produced by a clonal plasma cell dyscrasia accumulate in tissues and damage vital organs.
  • Treatment regimens used in multiple myeloma can be effective in AL amyloidosis; however, patients with this disease often tolerate these regimens poorly because of multisystem organ dysfunction.
  • In this report, we describe results of a phase 2 trial of the use of lenalidomide, as a single agent and in combination with dexamethasone, for the treatment of AL amyloidosis.
  • Thirty-four patients with AL amyloidosis, most with prior therapies, were enrolled in the trial.
  • Fatigue and myelosuppression were the most common treatment-related adverse events (35%), while thromboembolic complications (9%) were the most serious.
  • [MeSH-major] Amyloidosis / drug therapy. Dexamethasone / administration & dosage. Immunoglobulin Light Chains / blood. Thalidomide / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Drug Tolerance. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Sep 16;116(11):1990-1 [20847211.001]
  • (PMID = 16960148.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / P01 HL68705
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone; F0P408N6V4 / lenalidomide
  •  go-up   go-down


69. Kawamura N, Kira J: [Treatment strategy for POEMS syndrome]. Brain Nerve; 2008 Jun;60(6):621-6
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment strategy for POEMS syndrome].
  • POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) is a paraneoplastic disease associated with an underlying plasma cell dyscrasia.
  • No large-scale controlled study providing convincing evidence for the treatment of this rare condition has thus for been conducted.
  • However, several lines of evidence have shown the efficacy of conventional therapies such as radiation, alkylator-based treatment, and corticosteroid therapy.
  • Recent studies have also proposed novel therapeutic strategies such as autologous peripheral blood stem cell transplantation (auto-PBSCT) and thalidomide, lenalidomide, and bevacizumab therapies.
  • We reviewed the current treatment strategies for POEMS syndrome and summarized them as follows;.
  • 2) Melphalan-predonisolone administration may be a treatment option for the patients with widespread bone lesions.
  • 3) High dose chemotherapy with auto-PBSCT is a promising novel approach that can lead to dramatic improvement particularly in patients with good systemic condition.
  • 4) Plasma exchange and immunoglobulin treatment are not recommended.
  • Finally, we emphasized that the efficacy of these therapies largely depends on the appropriate early diagnosis of POEMS syndrome.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. POEMS Syndrome / therapy. Peripheral Blood Stem Cell Transplantation. Thalidomide / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Bevacizumab. Combined Modality Therapy. Humans. Immunoglobulins / administration & dosage. Melphalan / administration & dosage. Plasma Exchange. Prednisolone / administration & dosage. Prognosis. Radiotherapy. Surgical Procedures, Operative. Transplantation, Autologous. Vascular Endothelial Growth Factor A / blood

  • Genetic Alliance. consumer health - POEMS syndrome.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18567357.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Immunoglobulins; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 4Z8R6ORS6L / Thalidomide; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  • [Number-of-references] 35
  •  go-up   go-down


70. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A, Litzow MR: Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med; 2002 Nov;113(7):549-55
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation for the management of primary systemic amyloidosis.
  • PURPOSE: To review the characteristics and outcomes of amyloidosis patients treated with high-dose chemotherapy and stem cell reconstitution.
  • All patients had evidence of a clonal plasma cell dyscrasia; those with nonimmunoglobulin forms of amyloidosis were excluded, as were those who had no symptoms of amyloidosis, purpura, carpal tunnel syndrome, or symptomatic multiple myeloma.
  • All patients received melphalan-based chemotherapy; 17 patients were conditioned with total body irradiation.
  • Treatment-related mortality for stem cell transplantation was 14% (9/66).
  • CONCLUSION: The number of organs involved before stem cell transplantation for amyloidosis is the most important factor in predicting subsequent survival.
  • Stem cell transplantation should be considered as a treatment option for selected patients with amyloidosis.
  • [MeSH-major] Amyloidosis / surgery. Stem Cell Transplantation
  • [MeSH-minor] Adult. Aged. Amyloid Neuropathies / surgery. Biomarkers / analysis. Biopsy. Cardiomyopathies / surgery. Female. Humans. Kidney Diseases / surgery. Liver Diseases / surgery. Male. Middle Aged. Peripheral Nerves / metabolism. Retrospective Studies. Survival Analysis. Transplantation Conditioning. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12459400.001).
  • [ISSN] 0002-9343
  • [Journal-full-title] The American journal of medicine
  • [ISO-abbreviation] Am. J. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


71. Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, Wiesman J, Quillen K, Swan N, Wright DG: High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med; 2004 Jan 20;140(2):85-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
  • BACKGROUND: AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains.
  • Treatment with oral chemotherapy is minimally effective.
  • OBJECTIVE: To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m2) and autologous blood stem-cell transplantation.
  • INTERVENTION: High-dose chemotherapy and autologous stem-cell transplantation for patients who met eligibility requirements based on organ involvement and clinical status.
  • MEASUREMENTS: Survival analysis of all patients evaluated and a detailed analysis of treatment outcome in the subgroup that received high-dose melphalan and stem-cell transplantation.
  • RESULTS: Among 701 patients with AL amyloidosis, 394 (56%) were eligible for high-dose melphalan and stem-cell transplantation; 82 did not proceed with treatment because of patient choice or disease progression.
  • Median survival of the 312 patients who initiated treatment was 4.6 years.
  • A complete hematologic response, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of patients and was associated with prolonged survival.
  • Statistically significant improvements occurred in end-organ disease and were greater in patients with a complete hematologic response.
  • Mortality rate within 100 days of treatment with high-dose melphalan and stem-cell transplantation was 13%; patients with cardiomyopathy had the highest mortality rates.
  • CONCLUSIONS: Treatment of selected patients with AL amyloidosis by using high-dose melphalan and stem-cell transplantation resulted in hematologic remission, improved 5-year survival, and reversal of amyloid-related disease in a substantial proportion.
  • [MeSH-major] Amyloidosis / therapy. Melphalan / administration & dosage. Stem Cell Transplantation


72. Lin CK, Sung YC: Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents. Hematol Oncol Stem Cell Ther; 2009;2(3):385-93
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Newly diagnosed multiple myeloma in Taiwan: the evolution of therapy, stem cell transplantation and new treatment agents.
  • Multiple myeloma is a clonal plasma cell dyscrasia with clinical heterogeneity.
  • One is whether the patient is a candidate for high-dose chemotherapy with stem cell support and the other is risk stratification.
  • As novel therapeutics have emerged, it is increasingly important to introduce a risk-adapted approach.
  • The heterogeneity of the disease is established, for the most part, by disease biology, predominantly genetics.
  • This group of patients may not respond well to high-dose chemotherapy and require early introduction of newer treatments such as the bortezomib-containing regimen.
  • The main factor in determining the eligibility for stem cell transplants is age.
  • Based on the current literature and situation in Taiwan, we suggest stem cell transplantation if the patient is younger than 55 years of age.
  • Finally, we have also reviewed the status and the treatment of multiple myeloma in Taiwan.
  • Fortunately, there has been an improvement in awareness, diagnosis and treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Multiple Myeloma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Combined Modality Therapy. Humans. Taiwan

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139051.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 104
  •  go-up   go-down


73. Casserly LF, Fadia A, Sanchorawala V, Seldin DC, Wright DG, Skinner M, Dember LM: High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease. Kidney Int; 2003 Mar;63(3):1051-7
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
  • BACKGROUND: The development of end-stage renal disease (ESRD) is common among patients with amyloid light-chain AL amyloidosis-associated renal disease and survival of these patients is poor.
  • High-dose intravenous melphalan and autologous stem cell transplantation induce remission of the plasma cell dyscrasia in a significant proportion of patients with AL amyloidosis.
  • The efficacy and tolerability of such treatment for patients with AL amyloidosis-associated ESRD are unknown.
  • METHODS: Between June 1994 and June 2000, 15 patients with AL amyloidosis-associated ESRD were treated with intravenous melphalan (70 to 200 mg/m2) and autologous peripheral blood stem cell transplantation.
  • Clinical and laboratory data were prospectively collected prior to treatment, during the peritransplant period, and at 3 months, 12 months, and annually thereafter.
  • Treatment outcomes and toxicities were compared with 180 non-ESRD patients treated during the study period.
  • RESULTS: Eight of 15 patients (53%) had a hematologic complete response following treatment.
  • Median survival for the ESRD patients with a hematologic complete response was 4.5 years.
  • CONCLUSION: High-dose intravenous melphalan with stem cell transplantation is an effective treatment in selected patients with AL amyloidosis-associated ESRD.
  • Although the toxicity profile is greater in ESRD patients, the treatment offers the possibility of successful renal transplantation if hematologic remission is achieved.
  • This treatment should be considered for patients with AL amyloidosis-associated ESRD.
  • [MeSH-major] Amyloidosis / drug therapy. Antineoplastic Agents, Alkylating / administration & dosage. Kidney Failure, Chronic / drug therapy. Melphalan / administration & dosage. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12631087.001).
  • [ISSN] 0085-2538
  • [Journal-full-title] Kidney international
  • [ISO-abbreviation] Kidney Int.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


74. Rives S, Bladé J, Martínez C, Marín P, Carreras E, Montserrat E: [High-dose melphalan treatment followed by hematopoietic progenitor cell rescue in primary amyloidosis]. Med Clin (Barc); 2000 Jul 8;115(6):216-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose melphalan treatment followed by hematopoietic progenitor cell rescue in primary amyloidosis].
  • [Transliterated title] Tratamiento con melfalán a altas dosis seguido de rescate con progenitores hematopoyéticos en la amiloidosis primaria.
  • BACKGROUND: Primary systemic amyloidosis (AL) is a plasma cell dyscrasia characterized by the extracellular deposition of immunoglobulins light chains in different organs and systems.
  • Median survival with current standard treatment is less than 2 years.
  • Intensive chemotherapy followed by hematopoietic stem cell rescue has been used in AL for the last five years.
  • The reported results are encouraging, with a high response rate (65%).
  • Nonetheless, this procedure is associated to an important toxicity, with high transplant related mortality (about 25%).
  • In patients with advanced AL (more than two involved organs) and/or complicated cardiac disease, the mortality is particularly high.
  • In the current report we describe the outcome of the first five patients who received high dose therapy for AL at our institution.
  • PATIENTS AND METHODS: This treatment was administered to patients up to the age of 70 years, who met the standard eligibility criteria for an autologous bone marrow transplantation.
  • Intensive treatment consisted of melphalan 200 mg/m2 in all patients but one who received 140 mg/m2.
  • Both patients had a poor performance status and advanced disease, with more than two organs involved.
  • CONCLUSIONS: High dose therapy (HDT) with stem cell rescue in AL produces a high response rate.
  • Nevertheless, this treatment approach is associated to a high toxicity.
  • [MeSH-major] Amyloidosis / therapy. Antineoplastic Agents, Alkylating / administration & dosage. Hematopoietic Stem Cell Transplantation. Melphalan / administration & dosage
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Postoperative Complications. Time Factors

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. MELPHALAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Med Clin (Barc) 2000 Oct 21;115(13):486
  • (PMID = 11002461.001).
  • [ISSN] 0025-7753
  • [Journal-full-title] Medicina clínica
  • [ISO-abbreviation] Med Clin (Barc)
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] SPAIN
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


75. Yoshida T, Matsuda M, Katoh N, Tazawa K, Shimojima Y, Gono T, Ishii W, Nakazawa Y, Sakashita K, Koike K, Yamada T, Ikeda S: Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis. Intern Med; 2008;47(20):1783-90
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up of plasma cells in bone marrow and serum free light chains in primary systemic AL amyloidosis.
  • OBJECTIVE: Primary systemic AL amyloidosis arises from immunoglobulin light chains produced by plasma cell dyscrasia.
  • To prospectively investigate the production of M-protein and plasma cells in bone marrow before and after chemotherapy, we performed flow cytometry and analysis of serum free light chains (FLCs).
  • PATIENTS AND METHODS: Fifty-nine patients with primary systemic AL amyloidosis (mean age, 59.9+/-8.8 years) were enrolled in this study, and of these 31 were serially studied before and after chemotherapy.
  • After chemotherapies, such as high-dose melphalan with autologous stem cell support, 20 of 31 patients with AL amyloidosis achieved complete hematological remission.
  • There were no significant differences in any subtype of plasma cells before treatment between the remission and non-remission groups, but in the former group MPC-1(+)CD45(-)CD49e(-) and MPC-1(-)CD45(+) were significantly decreased and increased after chemotherapy compared with before, respectively.
  • CONCLUSION: Abnormal plasma cells in the bone marrow, particularly the MPC-1(+)CD45(-)CD49e(-) subset, may be important as a follow-up marker before and after chemotherapy in primary systemic AL amyloidosis.
  • [MeSH-major] Amyloidosis / blood. Amyloidosis / pathology. Bone Marrow / pathology. Immunoglobulin Light Chains / blood. Plasma Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD45 / blood. Biomarkers / blood. Case-Control Studies. Chemokine CCL2 / blood. Connectin. Creatinine / blood. Drug Therapy. Female. Follow-Up Studies. Humans. Integrin alpha5 / blood. Longitudinal Studies. Male. Middle Aged. Muscle Proteins / blood. Prognosis. Prospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18854629.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / CCL2 protein, human; 0 / Chemokine CCL2; 0 / Connectin; 0 / Immunoglobulin Light Chains; 0 / Integrin alpha5; 0 / Muscle Proteins; AYI8EX34EU / Creatinine; EC 3.1.3.48 / Antigens, CD45; EC 3.1.3.48 / PTPRC protein, human
  •  go-up   go-down


76. Wilson KS: Regression of follicular lymphoma with Devil's Claw: coincidence or causation? Curr Oncol; 2009 Aug;16(4):67-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cancer patients frequently use alternative therapies.
  • Two follicular lymphoma patients who had objective tumour regression after taking Devil's Claw without cytotoxic therapy are reported here.
  • METHODS AND RESULTS: Patient 1 presented with coexistent immunoglobulin G plasma cell dyscrasia and stage iiia lymphoma (nodes 5 cm in diameter).
  • Computed tomography scan 10 months later showed partial regression.
  • This patient later developed overt myeloma, at which time he stopped the herbal supplements and underwent high-dose chemotherapy and stem cell transplantation, since which no lymphoma progression has occurred.
  • Computed tomography scan 11 months later showed decreased adenopathy and splenomegaly, which has been sustained for 4 years.
  • Inhibition of COX-2 has a role in colon cancer prevention, has been implicated in lymphomagenesis, and is associated both with lymphoma stage and with response to treatment.
  • However, spontaneous regression in lymphoma has been reported in 16% of patients in one series, of whom none were on herbal medications or COX-2 inhibitors.
  • The key issue in both these patients is whether disease regression was "spontaneous" or causally related to therapy with Devil's Claw.
  • Further investigation is warranted, preferably with a COX-2 inhibitor of known purity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Res. 2004 Feb;28(2):179-90 [14654083.001]
  • [Cites] Leuk Lymphoma. 2004 Jul;45(7):1395-9 [15359639.001]
  • [Cites] Lancet. 2003 Aug 16;362(9383):516-22 [12932382.001]
  • [Cites] N Engl J Med. 2000 Jun 29;342(26):1946-52 [10874062.001]
  • [Cites] J Clin Oncol. 2008 Oct 1;26(28):4579-86 [18662969.001]
  • [Cites] Anticancer Res. 2007 Nov-Dec;27(6B):3875-82 [18225545.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4784-91 [15731178.001]
  • [Cites] Cancer. 1998 Aug 15;83(4):777-82 [9708945.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):1110-7 [9060552.001]
  • [Cites] Q J Med. 1991 Aug;80(292):651-60 [1754669.001]
  • [Cites] Semin Hematol. 1988 Apr;25(2 Suppl 2):11-6 [2456618.001]
  • [Cites] Am J Hematol. 1989 Jun;31(2):138-41 [2660545.001]
  • [Cites] N Engl J Med. 1984 Dec 6;311(23):1471-5 [6548796.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):2093-9 [7427915.001]
  • [Cites] Cancer. 1980 May 15;45(10):2627-32 [7378996.001]
  • [Cites] Ann Intern Med. 1979 Jan;90(1):10-3 [369420.001]
  • [Cites] J Pharmacol Sci. 2003 Nov;93(3):367-71 [14646256.001]
  • (PMID = 19672427.001).
  • [ISSN] 1198-0052
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2722058
  • [Keywords] NOTNLM ; Low-grade lymphoma / alternative therapy / cox-2 inhibition
  •  go-up   go-down


77. Bayer-Garner IB, Smoller BR: The spectrum of cutaneous disease in multiple myeloma. J Am Acad Dermatol; 2003 Apr;48(4):497-507
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of cutaneous disease in multiple myeloma.
  • BACKGROUND: Multiple myeloma (MM) is a plasma cell dyscrasia characterized by a clonal proliferation of plasma cells that produces a monoclonal protein.
  • There are dermatologic disorders that have been associated with MM, such as amyloidosis, cryoglobulinemia, POEMS syndrome, normolipemic plane xanthoma, and plasmacytoma.
  • DESIGN: We reviewed 2357 pathology reports of all patients with a diagnosis of MM to find those who had undergone a skin biopsy.
  • Files were searched for bone-marrow diagnosis, and for type and number of transplants.
  • Skin biopsy specimen diagnoses included neoplastic lesions, (111; 73 malignant, 38 benign), graft-versus-host disease (120), drug-related lesions (46), cutaneous eruption of lymphocyte recovery (3), thrombocytopenia-related lesions (9), normolipemic plane xanthoma (1), amyloidosis (1), Sweet's syndrome (7), panniculitis (1), papulosquamous lesions (18), bullous diseases (17), vasculitis (11), infectious lesions (41), granulomatous dermatitis (6), alopecia cicatrisata (1), nonspecific lesions (77), and unrelated lesions (2).
  • CONCLUSIONS: Skin biopsy specimens from patients with MM less than 60 days from transplant most commonly show sequelae of the transplant such as graft-versus-host disease, Grover's disease (as a result of leukocytopenia and fever, waiting for engraftment), drug eruptions, chemotherapy effect, thrombocytopenic effect, cutaneous eruption of lymphocyte recovery, and Sweet's syndrome (possibly as a result of granulocyte-macrophage colony-stimulating factor).
  • Biopsy specimens taken more than 60 days from transplant most commonly show graft-versus-host disease, drug eruptions, and Sweet's syndrome but also show unrelated conditions such as neoplastic lesions, nevi, papulosquamous lesions, vasculitis, infections, and nonspecific changes.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. Bone Marrow Transplantation / adverse effects. Female. Graft vs Host Disease / pathology. Humans. Male. Middle Aged. Skin / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12664010.001).
  • [ISSN] 0190-9622
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Tazawa K, Matsuda M, Yoshida T, Gono T, Katoh N, Shimojima Y, Ishii W, Fushimi T, Koyama J, Ikeda S: Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients. Intern Med; 2008;47(17):1517-22
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic outcome of cyclic VAD (vincristine, doxorubicin and dexamethasone) therapy in primary systemic AL amyloidosis patients.
  • OBJECTIVE: Intensive chemotherapy targeting plasma cell dyscrasia has been recently employed for the treatment of primary systemic AL amyloidosis.
  • We prospectively studied the clinical usefulness of cyclic VAD (vincristine, doxorubicin and dexamethasone) in patients with primary systemic AL amyloidosis who were ineligible for high-dose melphalan with autologous stem cell support.
  • RESULTS: Four patients (50%) showed a marked decrease in abnormal plasma cells in the bone marrow and normalized kappa/lambda ratios of serum free light chain in conjunction with disappearance of M-protein after 1 to 3 courses of VAD.
  • CONCLUSION: Cyclic VAD is a potent therapeutic option in primary systemic AL amyloidosis, but in patients with renal or cardiac dysfunction careful management for adverse events, especially body fluid retention, is necessary.
  • [MeSH-major] Amyloidosis / drug therapy. Amyloidosis / mortality. Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • [MeSH-minor] Aged. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Myeloma Proteins / antagonists & inhibitors. Prospective Studies. Survival Rate / trends. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758127.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Myeloma Proteins; 0 / multiple myeloma M-proteins; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  •  go-up   go-down


79. Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F: Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients. Arch Cardiovasc Dis; 2008 Sep;101(9):523-32
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Immunoglobulinic (AL) amyloidosis is a complication of plasma cell dyscrasia, characterized by widespread deposition of amyloid fibrils derived from monoclonal light chains.
  • Cardiac amyloid is the main prognostic factor, with a median survival of six months.
  • Cardiac transplantation in AL amyloidosis is associated with high mortality, due to disease recurrence in the allograft and systemic progression.
  • Suppression of light chain (LC) production with chemotherapy by melphalan plus dexamethasone (MD) or high dose melphalan followed by autologous stem cell transplantation (HDM/ASCT) improves survival.
  • However, both the indications and results of chemotherapy in patients transplanted for cardiac AL amyloidosis remain unclear.
  • AIMS: To assess the outcome of cardiac transplantation and haematological therapy in patients with cardiac AL amyloidosis.
  • In 2 patients not treated before transplantation, post-operative treatment with MD resulted in complete hematological remission in one.
  • CONCLUSION: Appropriate haematological therapy, including MD, may result in a survival benefit in AL amyloidosis patients with advanced heart failure requiring transplantation.
  • [MeSH-minor] Adult. Combined Modality Therapy. Dexamethasone / therapeutic use. Female. France. Hematopoietic Stem Cell Mobilization. Humans. Male. Melphalan / therapeutic use. Middle Aged. Myeloablative Agonists / therapeutic use. Recurrence. Retrospective Studies. Stem Cell Transplantation. Time Factors. Transplantation, Autologous. Treatment Outcome


80. Singh D, Wadhwa J, Kumar L, Raina V, Agarwal A, Kochupillai V: POEMS syndrome: experience with fourteen cases. Leuk Lymphoma; 2003 Oct;44(10):1749-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The POEMS syndrome, also known as Crow-Fukase disease, is a rare multisystem disorder, which may take several years to evolve fully.
  • Herein, we report a series of 14 cases with POEMS syndrome at our centre over the past 8 years, which were analysed retrospectively for their clinical features, response to therapy and treatment outcome.
  • Presence of plasma cell dyscrasia (PCD) was essential for inclusion in this study.
  • Patients were excluded from study if there was a secondary cause of polyneuropathy like amyloidosis, drugs like vincristine, nerve root or spinal cord compression.
  • An association with Castleman's disease and vasculitis was also noted.
  • With different chemotherapy protocols, all treated patients (n = 12), had significant symptomatic improvement with or without objective improvement at median follow up of 48 months (range 6-120).
  • [MeSH-minor] Adult. Aged. Female. Humans. India. Male. Middle Aged. Paraproteinemias / diagnosis. Paraproteinemias / therapy. Retrospective Studies

  • Genetic Alliance. consumer health - POEMS syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14692529.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Mele G, Pinna S, Melpignano A, Quarta G: Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens. Clin Ther; 2010 May;32(5):915-9
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective case series of three patients with plasma cell leukemia treated with bortezomib-based regimens.
  • BACKGROUND: Data from the literature have suggested that bortezomib is the only effective agent in the treatment of plasma cell leukemia (PCL), a type of plasma cell dyscrasia characterized by poor prognosis despite conventional chemotherapy including autologous and allogeneic transplantation.
  • These patients were treated with bortezomib variously combined with other drugs outside of clinical trials.
  • Patients 1 and 2 received bortezomib-based regimens (bortezomib 1.3 mg/m2 i.v. once daily on days 1, 4, 8, and 11; dexamethasone 20 mg i.v. once daily on days 1-4 and 8-11; oral cyclophosphamide 50 mg once daily on days 1-21, every 28 days) after 2 previous chemotherapeutic treatments.
  • In all 3 patients, circulating plasma cells persisted.
  • Patients 1 and 2 were not considered candidates for autologous peripheral blood stem cell transplantation (PBSCT) because of their nonresponse to the bortezomib-based regimens and severe deterioration of their clinical conditions (kidney and liver failure) due to disease progression.
  • After further treatment according to the modified protocol for patients with acute lymphatic leukemia (cyclophosphamide 800 mg/m2 i.v. on day 1 and 200 mg/m2 i.v. on days 2-5; vincristine 1.5 mg/m2 i.v. once daily on days 1, 8, and 15; doxorubicin 40 mg/m2 i.v. on day 1; methotrexate 1200 mg/m2/h i.v.
  • The patient died 5 months later because of disease progression.
  • CONCLUSION: These 3 patients with primary or secondary PCL who received a bortezomib-based regimen as rescue medication did not respond to treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Leukemia, Plasma Cell / drug therapy. Pyrazines / administration & dosage

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Excerpta Medica Inc. All rights reserved.
  • (PMID = 20685499.001).
  • [ISSN] 1879-114X
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


82. Messiaen T, Deret S, Mougenot B, Bridoux F, Dequiedt P, Dion JJ, Makdassi R, Meeus F, Pourrat J, Touchard G, Vanhille P, Zaoui P, Aucouturier P, Ronco PM: Adult Fanconi syndrome secondary to light chain gammopathy. Clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore); 2000 May;79(3):135-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pioneering work by Maldonado and associates (35), who reviewed the first 17 cases in 1975, led to the unifying concept that patients with FS and Bence Jones proteinuria have a special form of plasma cell dyscrasia characterized by slow progression of the tumor and by prominent crystal formation in proximal tubule cells, in the absence of myeloma casts in the distal tubule.
  • Moreover, 10 of the kappa light chains could be entirely or partially sequenced and tested for their resistance to cathepsin B, a lysosomal protease present in proximal tubule cells.
  • One patient of this group also had numerous crystals in proximal tubule cells.
  • The eleventh patient had complete FS with MGUS, but no crystals in proximal tubule cells even after electron microscopy.
  • First, they all were of the kappa type.
  • Resistance of V kappa to proteolysis in FS patients can explain the accumulation of the light chain in the endocytotic compartment of the proximal tubule cells, leading to impairment of proximal tubule functions.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunoglobulin Light Chains / chemistry. Immunoglobulin Light Chains / urine. Immunoglobulin kappa-Chains / chemistry. Immunoglobulin kappa-Chains / urine. Kidney Tubules, Proximal / pathology. Male. Middle Aged. Multiple Myeloma / etiology. Multiple Myeloma / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10844934.001).
  • [ISSN] 0025-7974
  • [Journal-full-title] Medicine
  • [ISO-abbreviation] Medicine (Baltimore)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains; 0 / Immunoglobulin kappa-Chains
  • [Number-of-references] 66
  •  go-up   go-down


83. Santos ES, Goodman M, Byrnes JJ, Fernandez HF: Thalidomide effects in the post-transplantation setting in patients with multiple myeloma. Hematology; 2004 Feb;9(1):35-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thalidomide recently has been proven to have an impact on plasma cell dyscrasia through multiple mechanisms.
  • We report on 12 cases (9 males and 3 females), median age 56 years old (range 41-65 years old) who underwent autologous peripheral stem cell transplantation for multiple myeloma and received thalidomide as maintenance therapy post-transplantation.
  • Patients received various cytoreductive therapies prior to stem cell harvest.
  • Eleven patients were in partial remission (PR) and one in complete remission (CR) on entry into the transplant phase of therapy.
  • One patient failed to tolerate thalidomide due to CNS symptoms and stopped therapy at 12 days.
  • Another patient stopped thalidomide therapy after 71 days, because of severe fatigue secondary to hypothyroidism.
  • Neutropenia, previously reported as an adverse effect in this setting, was not seen to date in our cohort.
  • CONCLUSION: Thalidomide appears to be a safe drug in the post-transplant setting, perhaps adding to the response achieved post-transplant without major toxicity.
  • Longer follow up and future randomized trials will be needed to validate the role of thalidomide and its long-term effect when used as maintenance therapy in the post-transplant setting.
  • [MeSH-major] Multiple Myeloma / therapy. Peripheral Blood Stem Cell Transplantation / methods. Thalidomide / administration & dosage. Thalidomide / toxicity
  • [MeSH-minor] Aged. Antigens, CD34 / analysis. Drug Evaluation. Female. Follow-Up Studies. Graft Survival. Humans. Male. Middle Aged. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14965866.001).
  • [ISSN] 1024-5332
  • [Journal-full-title] Hematology (Amsterdam, Netherlands)
  • [ISO-abbreviation] Hematology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD34; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


84. Berk JL, Keane J, Seldin DC, Sanchorawala V, Koyama J, Dember LM, Falk RH: Persistent pleural effusions in primary systemic amyloidosis: etiology and prognosis. Chest; 2003 Sep;124(3):969-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Restrictive cardiomyopathy frequently complicates primary systemic amyloidosis (AL), yet only a small number of these patients develop large pleural effusions refractory to diuretic therapy and thoracentesis.
  • We hypothesized that disruption of pleural function by amyloid deposits underlies persistent pleural effusions (PPEs) in patients with AL disease.
  • Indexes of plasma cell dyscrasia, nephrotic syndrome, thyroid function, and echocardiographic measures of left and right ventricle performance were compared between groups.
  • No statistical differences were found between the PPE and cardiac groups in echocardiographic measures of septal thickness, left ventricular systolic function, or diastolic compliance.
  • Renal function, plasma protein levels, and thyroid function were the same between groups.
  • Autopsy samples of parietal pleura were negative for disease in two cardiac patients.
  • PPE signaled limited survival among patients who were ineligible for treatment.
  • Survival after intensive chemotherapy and autologous stem cell transplantation was comparable in the PPE and cardiac groups (21.8 vs 15.6 months, respectively; p = 0.405).

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12970025.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Grant] United States / FDA HHS / FD / FD-R 001346; United States / NHLBI NIH HHS / HL / HL 68705
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


85. Hussein MA, Juturi JV, Rybicki L, Lutton S, Murphy BR, Karam MA: Etanercept therapy in patients with advanced primary amyloidosis. Med Oncol; 2003;20(3):283-90
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etanercept therapy in patients with advanced primary amyloidosis.
  • No effective treatment exists for primary amyloidosis, a plasma cell dyscrasia characterized by deposition of amyloid fibrils consisting of monoclonal light chains in various organs.
  • TNF-alpha has been implicated in other amyloid disorders; therefore, we used etanercept to treat patients with advanced amyloidosis who had failed other therapies or were ineligible for other treatment regimens.
  • For the entire group, improvement in performance status was statistically significant (p = 0.001), estimated median survival is 24.2 mo, 8 of whom are still alive with a median survival is 26.6 mo.
  • Six of those 12 patients are still alive, with a median survival is 26.6 mo.
  • The group of eight patients with severe cardiac involvement showed an estimated median survival of 13.2 mo, three of whom are still alive with a median survival is 25.9 mo.
  • Median survival for the patients with severe cardiac involvement was 13.2 mo with 3/8 patients are alive with a median survival of 25+ mo.
  • These results, even though in a small group of patients, suggest that etanercept may provide a new therapeutic option for the management of amyloidosis that should be studied further.
  • [MeSH-major] Amyloidosis / drug therapy. Antirheumatic Agents / therapeutic use. Immunoglobulin G / therapeutic use. Receptors, Tumor Necrosis Factor / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Etanercept. Female. Heart Diseases / chemically induced. Heart Diseases / prevention & control. Humans. Male. Middle Aged. Recombinant Fusion Proteins / administration & dosage. Recombinant Fusion Proteins / therapeutic use. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Hematol. 1995 Jan;32(1):45-59 [7878478.001]
  • [Cites] N Engl J Med. 1997 Apr 24;336(17):1202-7 [9110907.001]
  • [Cites] Mayo Clin Proc. 1989 Dec;64(12):1505-19 [2513459.001]
  • [Cites] Scand J Immunol. 1996 May;43(5):551-5 [8633214.001]
  • [Cites] Cell. 1999 Apr 2;97(1):133-44 [10199409.001]
  • [Cites] Nephron. 1997;75(3):350-3 [9069459.001]
  • [Cites] Am J Med. 1985 Dec;79(6):708-16 [3934968.001]
  • [Cites] Neurosci Lett. 1997 Nov 28;238(1-2):17-20 [9464644.001]
  • [Cites] J Immunol. 1993 Aug 1;151(3):1548-61 [8393046.001]
  • [Cites] Med Oncol. 1999 Jul;16(2):104-9 [10456658.001]
  • [Cites] Blood. 1991 Jan 15;77(2):257-62 [1985692.001]
  • [Cites] Am J Hum Genet. 2001 Aug;69(2):301-14 [11443543.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):115-9 [10367790.001]
  • [Cites] Hematol Oncol. 1995 Mar-Apr;13(2):69-82 [7797195.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1062-6 [9920856.001]
  • [Cites] Blood. 1992 Apr 1;79(7):1817-22 [1558973.001]
  • [Cites] J Submicrosc Cytol Pathol. 1999 Jul;31(3):313-23 [10626000.001]
  • [Cites] J Rheumatol. 2001 Jun;28(6):1238-44 [11409115.001]
  • [Cites] Blood. 1998 May 15;91(10):3662-70 [9573002.001]
  • [Cites] Semin Hematol. 1995 Jan;32(1):60-79 [7878479.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1521-8 [10415055.001]
  • [Cites] Biochem Mol Biol Int. 1999 May;47(5):845-50 [10365255.001]
  • [Cites] Kidney Int Suppl. 1993 Jun;41:S88-95 [8320954.001]
  • [Cites] Kidney Int. 2001 May;59(5):1677-82 [11318938.001]
  • [Cites] Curr Opin Immunol. 2000 Aug;12(4):479-86 [10899034.001]
  • [Cites] Ann Med Interne (Paris). 2000 Dec;151(8):611-7 [11173703.001]
  • [Cites] Cancer Detect Prev. 1996;20(1):52-6 [8907203.001]
  • (PMID = 14514978.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; 0 / Recombinant Fusion Proteins; OP401G7OJC / Etanercept
  •  go-up   go-down


86. Ansari-Lari MA, Ali SZ: Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test? Diagn Cytopathol; 2004 Mar;30(3):178-81
Hazardous Substances Data Bank. C.I. DIRECT RED 28 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?
  • Fine-needle aspiration of abdominal fat pad (FNAFP) is commonly employed for the diagnosis of systemic amyloidosis, a disease with highly variable clinical manifestations, often presenting difficult patient management problems.
  • Major emphases were assessment of the clinical utility of the test, correlation with concurrent or subsequent biopsies, and treatment strategies.
  • The primary indications for FNAFP were monoclonal gammopathy (34%), cardiomyopathy (22%), renal insufficiency (20%), neuropathy (8%), plasma cell dyscrasia (6%), and other conditions (10%).
  • Twenty-one patients positive for amyloid, based on initial or follow-up biopsies, were managed symptomatically without any specific treatment for amyloidosis.
  • One patient, who was specifically treated for amyloidosis by melphalan and dexamethasone, died 1 wk after therapy.
  • Three patients with multiple myeloma and amyloidosis underwent chemotherapy.
  • An FNAFP result is often not considered clinically conclusive and is followed by further invasive procedures to detect amyloid (55% of our positive and 31% of our negative FNAFP cases were rebiopsied).
  • Although in the majority of cases diagnosis of amyloidosis did not alter the treatment strategies, a conclusive positive result helped in ruling out other underlying conditions as the cause of patients' symptoms.
  • [MeSH-major] Adipose Tissue / pathology. Amyloid / metabolism. Amyloidosis / diagnosis. Biopsy, Fine-Needle / methods

  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 14986298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Amyloid; 0 / Coloring Agents; 3U05FHG59S / Congo Red
  •  go-up   go-down


87. Aoki M, Kim T, Shimada T, Kuwamura M, Yamate J, Ohashi F: A primary hepatic plasma cell tumor in a dog. J Vet Med Sci; 2004 Apr;66(4):445-7
Hazardous Substances Data Bank. PREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A primary hepatic plasma cell tumor in a dog.
  • An 8-year-old female Shetland sheep dog had hyperproteinemia with a monoclonal gammopathy and a solid mass on the liver, which was histologically diagnosed as a plasma cell tumor.
  • After the treatment of surgery and chemotherapy, serum protein level reduced to the normal range and the gammopathy was disappeared.
  • These findings indicate the plasma cell tumor developed primarily from the liver.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15133277.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan
  •  go-up   go-down


88. Kim SJ, Kim J, Cho Y, Seo BK, Kim BS: Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia. Jpn J Clin Oncol; 2007 May;37(5):382-4
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
  • Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy.
  • More effective treatment strategies are therefore needed for this disorder.
  • Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide.
  • The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m(2) intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1-4.
  • Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation.
  • Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia, Plasma Cell / drug therapy

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17538191.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


89. Lachmann HJ, Gallimore R, Gillmore JD, Carr-Smith HD, Bradwell AR, Pepys MB, Hawkins PN: Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol; 2003 Jul;122(1):78-84
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy.
  • Monoclonal immunoglobulin light chains are deposited as amyloid fibrils in systemic AL (primary) amyloidosis, but the underlying plasma cell dyscrasias are often difficult to detect or unquantifiable.
  • The relationships between circulating monoclonal light chains, amyloid load and clinical outcome, and the relative efficacies of chemotherapy regimens aimed at suppressing monoclonal immunoglobulin production, have not been determined.
  • Circulating free immunoglobulin light chain (FLC) concentration was measured with a sensitive nephelometric immunoassay in 262 patients with AL amyloidosis, and followed serially in 137 patients who received either high-dose chemotherapy or one of two intermediate-dose cytotoxic regimens.
  • Among 86 patients whose abnormal FLC concentration fell by more than 50% following chemotherapy, 5-year survival was 88% compared with only 39% among those whose FLC did not fall by half (P < 0.0001).
  • The magnitude and duration of the FLC responses to intermediate- and high-dose chemotherapy regimens were similar.
  • Reduction of the amyloidogenic FLC by more than 50% was associated with substantial survival benefit, regardless of the type of chemotherapy used.
  • Clinical improvement following chemotherapy in AL amyloidosis is delayed, but treatment strategies can be guided by their early effect on serum FLC concentration.
  • [MeSH-major] Amyloid / analysis. Amyloidosis / drug therapy. Immunoglobulin Light Chains / blood
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / blood. Biomarkers / blood. Follow-Up Studies. Humans. Middle Aged. Nephelometry and Turbidimetry / methods. Serum Amyloid P-Component / metabolism. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12823348.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amyloid; 0 / Antibodies, Monoclonal; 0 / Biomarkers; 0 / Immunoglobulin Light Chains; 0 / Serum Amyloid P-Component; 0 / amyloid protein AL
  •  go-up   go-down


90. Engineer L, Dow EC, Braverman IM, Ahmed AR: Epidermolysis bullosa acquisita and multiple myeloma. J Am Acad Dermatol; 2002 Dec;47(6):943-6
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The coexistence in the same patient of epidermolysis bullosa acquisita (a rare, autoimmune, acquired mucocutaneous blistering disorder) and multiple myeloma (a plasma cell neoplasm) is extremely uncommon.
  • [MeSH-minor] Biopsy, Needle. Dexamethasone / administration & dosage. Drug Therapy, Combination. Follow-Up Studies. Humans. Immunoglobulins, Intravenous / administration & dosage. Immunohistochemistry. Male. Middle Aged. Risk Assessment


91. Cheung WY, Greenberg CR, Bernstein K, Schacter B, Fourie T, Seftel MD: Type I Gaucher disease following chemotherapy for light chain multiple myeloma. Intern Med; 2007;46(15):1255-8
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type I Gaucher disease following chemotherapy for light chain multiple myeloma.
  • Although plasma cell disorders, such as hypergammaglobulinemia and monoclonal gammopathy of undetermined significance (MGUS), are reported to occur at higher incidences in patients with Type I Gaucher disease (GD) than in the normal population, pure light chain multiple myeloma (LCMM) has never been described in this context.
  • Our case is the first to highlight a patient with LCMM who developed clinically apparent GD only following chemotherapy and hematopoietic stem cell transplantation.
  • [MeSH-major] Gaucher Disease / chemically induced. Hematopoietic Stem Cell Transplantation / adverse effects. Multiple Myeloma / drug therapy
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. Female. Humans. Middle Aged. Nephrotic Syndrome / diagnosis. Nephrotic Syndrome / etiology


92. Tageja N, Nagi J, Valent J, Zonder J: Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy. South Med J; 2010 Jul;103(7):706-10
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cell leukemia presenting as organizing pneumonia refractory to high-dose steroid therapy.
  • A case of steroid-refractory organizing pneumonia (OP) as the initial presentation of plasma cell leukemia (PCL) in a patient who had no prior exposure to chemotherapy or radiation is described.
  • Since OP is traditionally a steroid-responsive disease, this case raises the possibility of a previously unknown patient subgroup with variable disease pattern and/or behavior in patients with plasma cell neoplasm.
  • [MeSH-major] Cryptogenic Organizing Pneumonia / diagnosis. Leukemia, Plasma Cell / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Glucocorticoids / therapeutic use. Humans. Lung / pathology. Middle Aged. Multiple Myeloma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20531051.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


93. Jimenez-Zepeda VH, Domínguez-Martínez VJ: Vincristine, doxorubicin, and dexamethasone or thalidomide plus dexamethasone for newly diagnosed patients with multiple myeloma? Eur J Haematol; 2006 Sep;77(3):239-44
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma (MM) is a malignant plasma cell tumor that is distributed at multiple sites within the bone marrow compartments.
  • High-dose dexamethasone regimens [including vincristine, doxorubicin, and dexamethasone (VAD) chemotherapy] induce rapid responses, and have resulted in improved survival for many patients when followed by intensive therapy with autologous stem cell support early in the disease course.
  • P = 0.0005. In summary, we conclude Thal/dex is an effective therapy in newly diagnosed MM inducing objective responses in over 84.3%.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Multiple Myeloma / drug therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16856924.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD I protocol
  •  go-up   go-down


94. Iseri M, Ozturk M, Ulubil SA: Synchronous presentation of extramedullary plasmacytoma in the nasopharynx and the larynx. Ear Nose Throat J; 2009 Nov;88(11):E9-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She was treated with a combination of surgery, radiotherapy, and chemotherapy.
  • We discuss the clinical features and treatment of plasma cell neoplasms in general and their three variants in particular.
  • [MeSH-major] Laryngeal Neoplasms / diagnosis. Larynx / pathology. Nasopharyngeal Neoplasms / diagnosis. Nasopharynx / pathology. Plasmacytoma / diagnosis
  • [MeSH-minor] Endoscopy. Female. Humans. Laryngoscopy. Middle Aged. Prognosis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19924656.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Wiesenthal AA, Nguyen BD: F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions. Clin Nucl Med; 2007 Oct;32(10):797-801
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multiple myeloma is the most common plasma cell neoplasm, with abnormal clonal proliferation of B cells in bone marrow.
  • Its staging is important for therapeutic management and prognosis.
  • Through imaging integration, PET provides functional detection of high metabolic lesions whereas CT provides correlated anatomic localization.
  • The authors present a case of multiple myeloma status post chemotherapy and stem cell transplant with diffuse osseous and extramedullary lesions evaluated by PET/CT.
  • [MeSH-major] Bone Neoplasms / diagnosis. Fluorodeoxyglucose F18. Multiple Myeloma / diagnosis. Positron-Emission Tomography / methods. Soft Tissue Neoplasms / diagnosis. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Staging. Radiopharmaceuticals. Subtraction Technique

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17885362.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


96. Chekhun VF, Tryndiak VP, Todor IM, Mykhaĭlenko VM, Kondrychyn IH, Dovbeshko HI, Repnyts'ka OP, Kulyk HI: [Phospholipid and cholesterol levels in the tumor cell plasma membranes with different sensitivity to doxorubicin]. Ukr Biokhim Zh (1999); 2003 Jul-Aug;75(4):120-5
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phospholipid and cholesterol levels in the tumor cell plasma membranes with different sensitivity to doxorubicin].
  • The investigation is aimed to study qualitative and quantitative composition of phospholipids, cholesterol content and lipids unsaturation index in plasma membranes of Guerin's carcinoma cells sensitive or resistant to doxorubicin.
  • The comparison of infrared spectra and phospholipids unsaturation index showed that the unsaturation level of fatty acids in plasma membrane from resistant cells was lower than that from sensitive carcinoma cells.
  • 31P-NMR spectroscopy of plasma membranes phospholipids shows the increase of phosphatidylserine and sphingomyeline content in plasma membrane isolated from resistant tumor as compared with sensitive tumor.
  • The levels of phosphatidylcholine and phosphatidylethanolamine were equal in drug-resistant and drug-sensitive carcinoma strains.
  • Changes in plasma membrane from resistant cells result in elevation of plasma membrane microviscosity and phosphatidylserine level increase can suggest the activation of P-glycoprotein-mediated efflux of doxorubicin.
  • [MeSH-major] Antibiotics, Antineoplastic / pharmacology. Cell Membrane / metabolism. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Membrane Fluidity / drug effects. Membrane Lipids / metabolism
  • [MeSH-minor] Animals. Cholesterol / metabolism. Male. Neoplasm Transplantation. Neoplasms, Experimental / drug therapy. Neoplasms, Experimental / metabolism. Neoplasms, Experimental / pathology. Phospholipids / metabolism. Rats. Rats, Wistar. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14681985.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] ukr
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Membrane Lipids; 0 / Phospholipids; 80168379AG / Doxorubicin; 97C5T2UQ7J / Cholesterol
  •  go-up   go-down


97. Turk HM, Komurcu S, Ozet A, Kuzhan O, Günhan O: An unusual presentation of extramedullary plasmacytoma in testis and review of the literature. Med Oncol; 2010 Dec;27(4):1378-80
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extramedullary plasmacytoma is a rare plasma cell neoplasm, and it is extremely uncommon in the testicles.
  • He received chemotherapy, melphalan and prednisolone, and palliative radiotherapy.
  • He succumbed to disease after 8 months.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / diagnosis. Orchiectomy. Plasmacytoma / diagnosis. Testicular Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):692-701 [12062614.001]
  • [Cites] Arch Pathol Lab Med. 1991 Jun;115(6):629-32 [1903919.001]
  • [Cites] JAMA. 1992 Nov 25;268(20):2946-51 [1433713.001]
  • [Cites] Br J Haematol. 2004 Mar;124(6):717-26 [15009059.001]
  • [Cites] Urology. 1989 Jul;34(1):51-4 [2665287.001]
  • [Cites] Crit Rev Oncol Hematol. 1988;8(2):93-152 [3046767.001]
  • [Cites] Br J Urol. 1964 Jun;36:SUPPL:85-94 [14184714.001]
  • [Cites] Radiother Oncol. 1990 Apr;17(4):293-303 [2343147.001]
  • [Cites] Am J Hematol. 2002 Oct;71(2):98-104 [12353308.001]
  • [Cites] Cancer. 1970 May;25(5):1193-203 [5443739.001]
  • [Cites] Cancer. 1999 Jun 1;85(11):2305-14 [10357398.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):113-20 [11316553.001]
  • [Cites] AMA Arch Pathol. 1952 Mar;53(3):262-72 [14902231.001]
  • [Cites] Urology. 1978 Jan;11(1):90-2 [622772.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):128-33 [7819027.001]
  • (PMID = 20035386.001).
  • [ISSN] 1559-131X
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Bogen B, Schenck K, Munthe LA, Dembic Z: Deletion of idiotype (Id)-specific T cells in multiple myeloma. Acta Oncol; 2000;39(7):783-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The variable (V) regions of myeloma proteins are unique to each plasma cell tumor, and therefore contain highly tumor-specific antigenic determinants called idiotopes (Id).
  • We suggest that Id-vaccination should be reserved for eradication of minimal residual disease, e.g. after high-dose chemotherapy and stem-cell transplantation.
  • [MeSH-minor] Animals. Cell Death. Cell Differentiation. Disease Progression. Hematopoietic Stem Cell Transplantation. Humans. Mice. Mice, Transgenic. Neoplasm, Residual. Vaccination

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145433.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Immunoglobulin Idiotypes; 0 / Myeloma Proteins
  •  go-up   go-down


99. Ishigaki T, Sasaki K, Watanabe K, Nakamura N, Toyota S, Kobayashi H, Tohda S: Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case. Cancer Genet Cytogenet; 2010 Aug;201(1):62-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.
  • The IGH/CCND1 fusion gene has been reported in many hematologic tumors such as mantle cell lymphoma, chronic lymphocytic leukemia, prolymphocytic leukemia, multiple myeloma, and plasma cell leukemia.
  • We report a case of plasma cell leukemia showing five IGH/CCND1 fusion signals by interphase fluorescence in situ hybridization (FISH).
  • Conventional cytogenetic analysis and multicolor spectral karyotyping showed a complex karyotype that did not include t(11;14).
  • The patient was treated with intensive chemotherapy.
  • The amplification of the IGH/CCND1 fusion gene may contribute to the aggressive course of the disease.
  • To our knowledge, this is the first case showing amplification of the IGH/CCND1 gene in plasma cell neoplasms.
  • [MeSH-major] Cyclin D1 / genetics. Immunoglobulin Heavy Chains / genetics. Leukemia, Plasma Cell / genetics

  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20633772.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / Immunoglobulin Heavy Chains; 136601-57-5 / Cyclin D1
  •  go-up   go-down


100. Mendenhall WM, Mendenhall CM, Mendenhall NP: Solitary plasmacytoma of bone and soft tissues. Am J Otolaryngol; 2003 Nov-Dec;24(6):395-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary plasmacytoma of bone and soft tissues.
  • PURPOSE: To define the optimal treatment and outcomes for patients with solitary plasmacytoma of bone and soft tissue.
  • RESULTS: Solitary plasmacytomas are uncommon and account for less than 5% of plasma cell neoplasms.
  • The optimal treatment is moderate-dose radiotherapy (40-50 Gy) and occasionally surgery.
  • Adjuvant chemotherapy does not improve survival.
  • CONCLUSION: Solitary plasmacytoma is an uncommon neoplasm that often arises in the head and neck.
  • Optimal treatment is moderate-dose radiotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Plasmacytoma / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Female. Humans. Male. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14608572.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down






Advertisement